<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2018.00092</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Glycogen Synthase Kinase 3&#x003B1; Is the Main Isoform That Regulates the Transcription Factors Nuclear Factor-Kappa B and cAMP Response Element Binding in Bovine Endothelial Cells Infected with <italic>Staphylococcus aureus</italic></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Silva-Garc&#x000ED;a</surname> <given-names>Octavio</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://frontiersin.org/people/u/364118"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Rico-Mata</surname> <given-names>Rosa</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://frontiersin.org/people/u/489392"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Maldonado-Pichardo</surname> <given-names>Mar&#x000ED;a Cristina</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bravo-Pati&#x000F1;o</surname> <given-names>Alejandro</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Valdez-Alarc&#x000F3;n</surname> <given-names>Juan J.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://frontiersin.org/people/u/485469"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Aguirre-Gonz&#x000E1;lez</surname> <given-names>Jorge</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Baizabal-Aguirre</surname> <given-names>V&#x000ED;ctor M.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor1">&#x0002A;</xref>
<uri xlink:href="http://frontiersin.org/people/u/227503"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Centro Multidisciplinario de Estudios en Biotecnolog&#x000ED;a, Facultad de Medicina Veterinaria y Zootecnia, Universidad Michoacana de San Nicol&#x000E1;s de Hidalgo</institution>, <addr-line>Morelia</addr-line>, <country>Mexico</country></aff>
<aff id="aff2"><sup>2</sup><institution>Global Health de M&#x000E9;xico S. A. de C. V.</institution>, <addr-line>Guadalajara</addr-line>, <country>Mexico</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Jason Paul Gigley, University of Wyoming, United States</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Marisa Mariel Fernandez, Instituto de Estudios de la Inmunidad Humoral (IDEHU), Argentina; Laura Noelia Cariddi, National University of R&#x000ED;o Cuarto, Argentina</p></fn>
<corresp content-type="corresp" id="cor1">&#x0002A;Correspondence: V&#x000ED;ctor M. Baizabal-Aguirre, <email>baizabal&#x00040;umich.mx</email>, <email>vmbaiza&#x00040;gmail.com</email></corresp>
<fn fn-type="other" id="fn001"><p>Specialty section: This article was submitted to Microbial Immunology, a section of the journal Frontiers in Immunology</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>29</day>
<month>01</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>9</volume>
<elocation-id>92</elocation-id>
<history>
<date date-type="received">
<day>26</day>
<month>10</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>01</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2018 Silva-Garc&#x000ED;a, Rico-Mata, Maldonado-Pichardo, Bravo-Pati&#x000F1;o, Valdez-Alarc&#x000F3;n, Aguirre-Gonz&#x000E1;lez and Baizabal-Aguirre.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>Silva-Garc&#x000ED;a, Rico-Mata, Maldonado-Pichardo, Bravo-Pati&#x000F1;o, Valdez-Alarc&#x000F3;n, Aguirre-Gonz&#x000E1;lez and Baizabal-Aguirre</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p>Glycogen synthase kinase 3 (GSK3) is a constitutive enzyme implicated in the regulation of cytokine expression and the inflammatory response during bacterial infections. Mammals have two GSK3 isoforms named GSK3&#x003B1; and GSK3&#x003B2; that plays different but often overlapping functions. Although the role of GSK3&#x003B2; in cytokine regulation during the inflammatory response caused by bacteria is well described, GSK3&#x003B1; has not been found to participate in this process. Therefore, we tested if GSK3&#x003B1; may act as a regulatory isoform in the cytokine expression by bovine endothelial cells infected with <italic>Staphylococcus aureus</italic> because this bacterium is one of the major pathogens that cause tissue damage associated with inflammatory dysfunction. Interestingly, although both isoforms were phosphorylated&#x02013;inactivated, we consistently observed a higher phosphorylation of GSK3&#x003B1; at Ser21 than that of GSK3&#x003B2; at Ser9 after bacterial challenge. During a temporal course of infection, we characterized a molecular switch from pro-inflammatory cytokine expression (IL-8), promoted by nuclear factor-kappa B (NF-&#x003BA;B), at an early stage (2&#x02009;h) to an anti-inflammatory cytokine expression (IL-10), promoted by cAMP response element binding (CREB), at a later stage (6&#x02009;h). We observed an indirect effect of GSK3&#x003B1; activity on NF-&#x003BA;B activation that resulted in a low phosphorylation of CREB at Ser133, a decreased interaction between CREB and the co-activator CREB-binding protein (CBP), and a lower expression level of IL-10. Gene silencing of GSK3&#x003B1; and GSK3&#x003B2; with siRNA indicated that GSK3&#x003B1; knockout promoted the interaction between CREB and CBP that, in turn, increased the expression of IL-10, reduced the interaction of NF-&#x003BA;B with CBP, and reduced the expression of IL-8. These results indicate that GSK3&#x003B1; functions as the primary isoform that regulates the expression of IL-10 in endothelial cells infected with <italic>S. aureus</italic>.</p>
</abstract>
<kwd-group>
<kwd>inflammatory response</kwd>
<kwd>endothelial cells</kwd>
<kwd><italic>Staphylococcus aureus</italic></kwd>
<kwd>glycogen synthase kinase 3</kwd>
<kwd>nuclear factor-kappa B</kwd>
<kwd>cAMP response element binding</kwd>
<kwd>interleukin-8</kwd>
<kwd>interleukin-10</kwd>
</kwd-group>
<contract-num rid="cn01">152518</contract-num>
<contract-sponsor id="cn01">Consejo Nacional de Ciencia y Tecnolog&#x000ED;a<named-content content-type="fundref-id">10.13039/501100007350</named-content></contract-sponsor>
<contract-sponsor id="cn02">Coordinaci&#x000F3;n de la Investigaci&#x000F3;n Cient&#x000ED;fica<named-content content-type="fundref-id">10.13039/501100006570</named-content></contract-sponsor>
<counts>
<fig-count count="9"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="60"/>
<page-count count="13"/>
<word-count count="9099"/>
</counts>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="introduction">
<title>Introduction</title>
<p><italic>Staphylococcus aureus</italic> is a Gram (&#x0002B;) bacterium that causes important infectious diseases among humans and animals. This bacterium expresses a broad range of virulence factors and cell-wall-associated structures (CWASs) that induce inflammation and are responsible for tissue damage (<xref ref-type="bibr" rid="B1">1</xref>). A hallmark of <italic>S. aureus</italic> is its ability to evade host innate immune response, which results in repeated infections and life-threatening diseases (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>). The molecular mechanisms that <italic>S. aureus</italic> employs to evade the host immune response are diverse, and some of them are poorly understood. One of these mechanisms involves an impairment in cell-signaling pathways leading to the suppression of interleukin-8 (IL-8) expression (<xref ref-type="bibr" rid="B4">4</xref>&#x02013;<xref ref-type="bibr" rid="B7">7</xref>), a cytokine that shows pro-inflammatory and chemotactic activities in the first stages of <italic>S. aureus</italic> infections (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>). Moreover, IL-8 is essential to promote neutrophil survival and bacterial clearance because the inhibition of IL-8 expression in <italic>S. aureus</italic> infection models has been associated with cell death and bacterial survival (<xref ref-type="bibr" rid="B6">6</xref>). <italic>S. aureus</italic> infections also enhance an anti-inflammatory response through the induction of immune-suppressive and -tolerogenic cytokines expression (i.e., interleukin-10 (IL-10)) that contribute to bacterial persistence and immune tolerance (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>).</p>
<p>Host cells can recognize <italic>S. aureus</italic> CWASs through the plasma membrane TLR2 receptor. The binding of CWAS to TLR2 activates the phosphoinositide 3-kinase/Akt (PI3K/Akt)-signaling pathway that mediates a variety of cellular responses such as survival, proliferation, differentiation, apoptosis, and inflammation (<xref ref-type="bibr" rid="B12">12</xref>). The activation of PI3K leads to Akt phosphorylation at Ser473 and Thr308 by the constitutively active PDK1 and mTORC2 (<xref ref-type="bibr" rid="B13">13</xref>). In turn, the activated Akt regulates the activity of a wide range of substrates, among which glycogen synthase kinase 3 (GSK3) regulates the balance of the inflammatory response (<xref ref-type="bibr" rid="B14">14</xref>). GSK3 refers to the two mammalian paralogs GSK3&#x003B1; and GSK3&#x003B2; (<xref ref-type="bibr" rid="B15">15</xref>), which are unusually constitutively active and can be inactivated by phosphorylation at Ser21 (GSK3&#x003B1;) or Ser9 (GSK3&#x003B2;) by Akt upon bacterial stimulus (<xref ref-type="bibr" rid="B16">16</xref>). Since its discovery, GSK3&#x003B2; has been proposed as the principal GSK3 isoform involved in the regulation of many cellular functions, including the inflammatory response caused by bacterial infections. The other isoform, GSK3&#x003B1;, has not yet been associated with the regulation of the inflammatory response. This observation is important because the same stimulus can usually phosphorylate and inactivate both isoforms. The experimental evidence suggests that the physiological roles of GSK3 isoforms may be explained by different regulatory mechanisms, such as the formation of molecular complexes, subcellular compartmentation, and specific kinase modifications that are linked to specific stimuli and cellular contexts (<xref ref-type="bibr" rid="B17">17</xref>).</p>
<p>In a previous report, we demonstrated that the internalization of <italic>S. aureus</italic> by bovine endothelial cells (BECs) induced the activity of PI3K/Akt signaling and a preferential phosphorylation of GSK3&#x003B1; compared to GSK3&#x003B2; (<xref ref-type="bibr" rid="B18">18</xref>). More recently, we reported that peptidoglycan from <italic>S. aureus</italic> induced a higher phosphorylation of GSK3&#x003B1; than that of GSK3&#x003B2;, and this led to an increase in IL-12p40 expression (<xref ref-type="bibr" rid="B19">19</xref>). Several, studies in murine models have shown that both isoforms of GSK3 are not physiologically redundant (<xref ref-type="bibr" rid="B20">20</xref>). The deletion of GSK3&#x003B1; in myeloid cells attenuated atherosclerosis and promoted M2 macrophage phenotype and IL-10 expression (<xref ref-type="bibr" rid="B21">21</xref>). Interestingly, GSK3 isoforms are differentially expressed, depending on the tissue analyzed. For example, GSK3&#x003B1; is the main isoform expressed in the skeletal muscle, testis, and neutrophils but it is absent in birds (<xref ref-type="bibr" rid="B17">17</xref>). Regarding GSK3&#x003B2;, this isoform is predominant in a Th17 subtype of T cells compared to GSK3&#x003B1;, indicating that GSK3&#x003B1; and GSK3&#x003B2; expressions are tissue-specific (<xref ref-type="bibr" rid="B22">22</xref>). Also, GSK3&#x003B1; but not GSK3&#x003B2; promotes IL-10 expression in a mice model of high-fat diet-low-density lipoprotein in response to a variety of stimuli (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B23">23</xref>), and it is the main isoform inactivated by the peptide neurotensin (<xref ref-type="bibr" rid="B24">24</xref>), which reduces inflammation after fibroblast stimulation with lipopolysaccharide (LPS) (<xref ref-type="bibr" rid="B25">25</xref>).</p>
<p>A molecular mechanism by which GSK3 regulates the balance in cytokines expression has been previously described in macrophages stimulated with LPS from <italic>Escherichia coli</italic>. It was observed that GSK3&#x003B2; regulated the pro- and anti-inflammatory cytokines expression through its influence on nuclear factor-kappa B (NF-&#x003BA;B) and cAMP response element-binding (CREB) activity (<xref ref-type="bibr" rid="B14">14</xref>). This mechanism involved the competition between CREB and NF-&#x003BA;B for the co-activator CREB-binding protein (CBP). According to this model, the activation of NF-&#x003BA;B is essential for IL-8 expression (<xref ref-type="bibr" rid="B26">26</xref>) and is positively favored by GSK3&#x003B2; (<xref ref-type="bibr" rid="B27">27</xref>). By contrast, GSK3&#x003B2; negatively regulates CREB by limiting its phosphorylation at Ser133 (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B28">28</xref>), which results in a reduced CREB-DNA-binding activity (<xref ref-type="bibr" rid="B29">29</xref>) and subsequently low IL-10 expression (<xref ref-type="bibr" rid="B30">30</xref>). However, our experimental evidence indicates that this GSK3-dependent regulation of NF-&#x003BA;B and CREB activity in BEC infected with <italic>S. aureus</italic> primarily depends on GSK3&#x003B1; rather than on GSK3&#x003B2;.</p>
<p>Therefore, we propose that in BEC infected with <italic>S. aureus</italic>, the constitutive activity of GSK3&#x003B1; favors NF-&#x003BA;B activation and expression of IL-8 at initial stages. However, GSK3&#x003B1; activity inhibition at later stages of infection favors CREB activation that leads to IL-10 expression. Our data highlight the regulatory role of the GSK3&#x003B1; isoform on the inflammatory response in endothelial cells and may explain, in part, why <italic>S. aureus</italic> infections can evolve to a chronic state.</p>
</sec>
<sec id="S2" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="S2-1">
<title>Media and Chemicals</title>
<p>DMEM/F12 (F12), Trypsin-EDTA, Igepal CA-930, Akt-IV, and SB216763 were purchased from Sigma&#x02013;Aldrich, Inc. (St. Louis, MO, USA). Fetal calf serum (FCS) was acquired from Equitech-Bio, Inc. (Kerrville, TX, USA). A cocktail of sodium penicillin G, streptomycin sulfate, and amphotericin B was purchased from Gibco-BRL (Gaithersburg, MD, USA). Halt-TM Phosphatase inhibitor cocktail was purchased from Thermo Fisher Scientific (Waltham, MA, USA). Protease inhibitor cocktail was acquired from GE Healthcare Biosciences (Little Chalfont, UK). Trizol reagent and EXPRESS One-Step SYBR GreenER Universal Kit were purchased from Invitrogen (Carlsbad, CA, USA). Bovine IL-10 and IL-8 TSZ ELISA kit were purchased from Biotang (Waltham, MA, USA). Plasmid pLKO.1-GSK3&#x003B2;-&#x00023;1 was a gift from Alex Toker (Addgene plasmid &#x00023;32497) and PLKO.1 plasmid was a gift from Bob Weinberg (Addgene plasmid &#x00023; 8453). pCF CREB M1 was a gift from Marc Montminy (Addgene plasmid &#x00023; 22969). The generation of pCF empty vector was done by the enzyme digestion of pCF CREB M1 with SacI restriction enzyme, and then the purification and ligation of the 5-kb fragment were generated.</p>
</sec>
<sec id="S2-2">
<title>Antibodies</title>
<p>Antibodies against Laminin A/C, GAPDH, &#x003B2;-actin, CREB, CBP, and IgG-HRP-coupled antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Antibodies against phospho-glycogen synthase (Ser641), phospho-GSK3&#x003B1; (Ser21), phospho-GSK3&#x003B1; (Ser9), phospho-NF-&#x003BA;B p65 (Ser536), phospho-CREB (Ser133), GSK3&#x003B2;, GSK3&#x003B1;, and NF-&#x003BA;B p65 were purchased from Cell Signaling Technology (Boston, MA, USA).</p>
</sec>
<sec id="S2-3">
<title>Bacterial Strain, Cell Line, and Culture Conditions</title>
<p>The strain of <italic>S. aureus</italic> used in this study is an isolate from a clinical case of bovine mastitis and was obtained from the American-Type Culture Collection (27543). Bacteria were cultured overnight in 3&#x02009;ml of Luria-Bertani (LB) medium at 37&#x000B0;C with continuous agitation. The inoculum for infection assays was prepared by adding 1&#x02009;ml of this pre-culture to 49&#x02009;ml of fresh LB medium and grown at 37&#x000B0;C. This inoculum was added to cells until the culture reached the initial-middle log phase at an optical density of 0.3 at 600&#x02009;nm and washed with F12 medium.</p>
<p>Endothelial cells used in this study were obtained from bovine umbilical veins and immortalized by transfection with an expression vector containing the E6&#x02013;E7 oncogenes of human papillomavirus 16 (BVE-E6&#x02013;E7) (<xref ref-type="bibr" rid="B31">31</xref>). These BECs were grown and maintained in F12 supplemented with 10% FCS and a cocktail of sodium penicillin G, streptomycin sulfate and amphotericin B, unless otherwise noted. For pretreatment with inhibitors, BECs were pre-incubated with a medium alone or with 1&#x02009;&#x000B5;M of Akt-IV, 10&#x02009;&#x000B5;M of SB216763, or 20&#x02009;&#x000B5;M of Parthenolide before infection with bacteria.</p>
</sec>
<sec id="S2-4">
<title>Infection Assay</title>
<p>Bovine endothelial cells were grown in six-well cell culture plates with F12 medium supplemented with FCS and antibiotics until 90&#x02013;95% confluence. Then, cells were washed 2&#x000D7; with PBS and the medium was changed to F12 without serum and antibiotics. Cells were left in these conditions for at least 4&#x02009;h. Bacteria were added at a multiplicity of infection (MOI) of 20&#x02009;CFU/cell, and plates were centrifuged at 500 &#x000D7; <italic>g</italic> for 5&#x02009;min and incubated in 5% CO<sub>2</sub> at 37&#x000B0;C for the times indicated.</p>
</sec>
<sec id="S2-5">
<title>BEC Transfection</title>
<p>For plasmids transfection containing siRNA against GSK3 isoforms, BECs were grown until 60&#x02013;70% confluence in F12 medium without serum and antibiotics for 24&#x02009;h. Then, transfection was performed with Lipofectamine 2000 from Thermo Fisher Scientific (Waltham, MA, USA); for siGSK3&#x003B1;, we added 3&#x02009;&#x000B5;g of siRNA-GSK3&#x003B1; plasmid (Sigma&#x02013;Aldrich) and 3&#x02009;&#x000B5;g of PLKO.1; for siGSK3&#x003B2;, we added 3&#x02009;&#x000B5;g of pLKO.1-GSK3&#x003B2;-&#x00023;1 and 3&#x02009;&#x000B5;g of PLKO.1; for siGSK3&#x003B1;&#x003B2;, we added 3&#x02009;&#x000B5;g of siRNA-GSK3&#x003B1; and 3&#x02009;&#x000B5;g of pLKO.1-GSK3&#x003B2;-&#x00023;1 plasmid; and for sicontrol, we added 6&#x02009;&#x000B5;g of PLKO.1. After 24&#x02009;h, the culture medium was changed to F12 with low serum (1%), and cells were incubated for 5&#x02009;days. GSK3&#x003B1; and GSK3&#x003B2; gene-silenced cells were screened by Western blotting. For GSK3&#x003B1;, the targeting sequence was 5&#x02032;-TACATCTGTTCTCGCTACTA-3&#x02032; (nucleotides 1535&#x02013;1554, pLKO.1-GSK3&#x003B1;), and for GSK3&#x003B2; the targeting sequence was 5&#x02032;-GAAGTCAGCTATACAGACACT-3&#x02032; (nucleotides 587&#x02013;607, pLKO.1-GSK3&#x003B2;). To express the CREB-dominant-negative mutant, cells were cultured at 70&#x02013;90% confluence in F12 medium without serum or antibiotics for 24&#x02009;h; then, 350&#x02009;ng of plasmid pCF-M1-CREB was transfected with Lipofectamine 2000 or 350&#x02009;ng of pCF empty vector. pCF-M1-CREB plasmid encodes a CREB mutant in which Ser133 was replaced by Ala133. After 12&#x02009;h, the medium was changed to fresh F12 and low serum, and cells were incubated for an extended period of 48&#x02009;h. The medium was changed to F12 without serum or antibiotics, and cells were left for at least 4&#x02009;h before stimulation with <italic>S. aureus</italic>. Transfection efficiency was monitored by detecting the FLAG tag present on the CREB-mutant construct in Western blot assays. The transfection efficiency of the empty pCF-M1 vector was monitored by the resistance of cells to Geneticin.</p>
</sec>
<sec id="S2-6">
<title>Protein Extraction, Subcellular Fractionation, and Western Blot Assay</title>
<p>To evaluate the relative abundance of phosphorylated and non-phosphorylated proteins, the total protein (cytosolic and nuclear) from control and treated cells was obtained by washing cells 2&#x000D7; with ice-cold PBS and lysing them with 80&#x02009;&#x000B5;l of cold lysis buffer (20&#x02009;mM Tris&#x02013;HCl, pH 7.5, 150&#x02009;mM NaCl, 1% Igepal CA-930, 10&#x02009;mM Na-pyrophosphate, 50&#x02009;mM NaF, and 1&#x02009;mM Na-orthovanadate) supplemented with 1&#x000D7; protease inhibitor cocktail and 1&#x000D7; phosphatase inhibitor cocktail, which were added immediately before lysis. For subcellular protein fractionation, we followed the REAP method described by Suzuky et al. (<xref ref-type="bibr" rid="B32">32</xref>). Lysates were centrifuged at 16,000 &#x000D7; <italic>g</italic> for 20&#x02009;min at 4&#x000B0;C, and the supernatant was recovered. Protein concentration was measured by Bradford using BSA as standard. Then, 30&#x02013;40&#x02009;&#x000B5;g of protein was separated by electrophoresis in 10% sodium dodecyl sulfate-polyacrylamide gels at 200&#x02009;V for 1&#x02009;h and electroblotted in a wet chamber onto 0.45&#x02009;&#x000B5;m nitrocellulose membrane (Bio-Rad) at 250&#x02009;mA for 1&#x02009;h. Membranes were incubated in a blocking solution (5% non-fat milk solution) in TTBS (10&#x02009;mM Tris&#x02013;HCl, pH 7.5, 0.9% NaCl, and 0.1% Tween 20); primary antibodies to target proteins were added and membranes incubated at 4&#x000B0;C overnight. Membranes washed 1&#x000D7; with PBS and 2&#x000D7; with TTBS were incubated with secondary antibodies. Proteins were detected with the Immobilon Western Chemiluminescent HRP substrate kit from Millipore (Billerica, MA, USA). Protein loading was verified by stripping the membranes with NaOH of 0.2&#x02009;N for 5&#x02009;min and washed 2&#x000D7; with TTBS; after a blocking step, the membranes were re-probed with antibodies against the indicated housekeeping proteins and detected in the same way as described. Data presented in Figures <xref ref-type="fig" rid="F4">4</xref> and <xref ref-type="fig" rid="F9">9</xref>C were obtained by scanning the membranes using a C-DiGit blot scanner (LI-COR, Lincoln, NE, USA).</p>
</sec>
<sec id="S2-7">
<title>RNA Extraction and Reverse Transcription and Real-time Quantitative PCR (qRT-PCR)</title>
<p>After infection, BECs were washed 2&#x000D7; with ice-cold PBS, and the total RNA was extracted with Trizol reagent, following the isolation procedure described by the manufacturer. RNA was purified with RQ1 RNase-free DNase (Promega). One-step qRT-PCR was performed using the EXPRESS One-Step SYBR GreenER Universal Kit and the real-time StepOnePlus thermocycler from Applied Biosystems. Each reaction was performed with 100&#x02009;ng of total RNA under the standard 20-&#x000B5;l reaction provided by Invitrogen. The one-step-cycling program conditions and oligonucleotide primers used were as described by Konnai et al. (2003) (<xref ref-type="bibr" rid="B33">33</xref>). Amplification of the expected single products was confirmed by single-peak analysis in temperature-melting curve and visualization on 1% agarose gels stained with ethidium bromide. Relative transcript levels of mRNA were calculated with the &#x00394;&#x00394;Ct method, using &#x003B2;-actin as the reference gene. Negative amplification of non-added RT enzyme reactions confirmed the absence of DNA in our assays.</p>
</sec>
<sec id="S2-8">
<title>Measurement of IL-8 and IL-10 Protein Levels</title>
<p>Bovine IL-8 and IL-10 proteins in culture supernatants were quantitated for the indicated times by sandwich ELISA, according to the manufacturer&#x02019;s instructions (Biotang, Waltham, MA, USA).</p>
</sec>
<sec id="S2-9">
<title>Co-IP Assays</title>
<p>Co-IP assays were performed with the Pierce Protein A/G Magnetic Beads kit (Thermo Fisher Scientific). Briefly, the control and infected cells (&#x0007E;1&#x02009;&#x000D7;&#x02009;10<sup>7</sup>) were washed 2&#x000D7; with ice-cold PBS and lysed in washing/lysis buffer supplemented with 1&#x000D7; protease inhibitor cocktail and 1&#x000D7; phosphatase inhibitor cocktail. Cell debris was collected by centrifugation at 18,000&#x02009;&#x000D7;&#x02009;<italic>g</italic> for 10&#x02009;min at 4&#x000B0;C. The supernatant was recovered and quantitated for protein concentration. Then, 5&#x02009;&#x000B5;g of CBP IP antibody was added to 500&#x02009;&#x000B5;g of protein extract; the volume was adjusted to 500&#x02009;&#x000B5;l with lysis buffer and incubated with continuous agitation overnight at 4&#x000B0;C. Then, 25&#x02009;&#x000B5;g of protein A/G magnetic beads was added and incubated for 1&#x02009;h with continuous agitation at room temperature (&#x0007E;23&#x000B0;C); beads were washed 2&#x000D7; with a washing buffer and 1&#x000D7; with water. The target antigen was eluted with 1&#x000D7; lane marker buffer and 50&#x02009;mM DTT in a final volume of 100&#x02009;&#x000B5;l. Then, 30&#x02009;&#x000B5;l of sample in elution buffer was loaded, and proteins were detected by Western blot as described earlier.</p>
</sec>
<sec id="S2-10">
<title>Statistical Analysis</title>
<p>The relative abundance of phosphorylated proteins was quantitated by densitometric analysis with the Image Processing and Analysis in Java Program ImageJ (<uri xlink:href="http://rsbweb.nih.gov/ij">http://rsbweb.nih.gov/ij</uri>). To calculate densitometric values, the intensity of the phosphorylated band was divided by the intensity of the non-phosphorylated one. These intensities were referred to a value of 1.0 that was arbitrarily assigned to the untreated control. The statistical significance of triplicate blots, IL-8 and IL-10 mRNA &#x00394;&#x00394;Ct value, and protein levels were evaluated with the Tukey HSD multiple-comparison test and one-way analysis of variance by using the JMP 6.0 program (SAS Institute). Differences between groups were considered significant at <italic>P</italic>&#x02009;&#x0003C;&#x02009;0.05. All data are available on request.</p>
</sec>
</sec>
<sec id="S3">
<title>Results</title>
<sec id="S3-1">
<title>Endothelial Cells Infected with <italic>S. aureus</italic> Express IL-8 and IL-10</title>
<p>The pro-inflammatory chemokine IL-8 is an early marker of bacterial infection (<xref ref-type="bibr" rid="B9">9</xref>). However, several authors have reported that <italic>S. aureus</italic> can induce or repress the IL-8 expression on different cellular physiological contexts, and this was correlated with the pathology produced by this bacterium (<xref ref-type="bibr" rid="B4">4</xref>&#x02013;<xref ref-type="bibr" rid="B7">7</xref>). There is also evidence that <italic>S. aureus</italic> induces IL-10 expression, leading to immune tolerance (<xref ref-type="bibr" rid="B11">11</xref>). Therefore, we asked whether the expression of these cytokines depended upon the stage of infection. In order to evaluate the kinetics of IL-8 and IL-10 expressions, BECs were infected with <italic>S. aureus</italic> at a MOI of 20, which allows the survival of endothelial cells for 2, 4, and 6&#x02009;h. Then, RNA was purified to analyze IL-8/IL-10 mRNA by qRT-PCR and their corresponding peptides in cell supernatants by ELISA. The expression of IL-8 mRNA increased by more than 2.5-fold in response to 2&#x02009;h of <italic>S. aureus</italic> infection; however, at longer infection times of 4&#x02013;6&#x02009;h, IL-8 mRNA values returned to control levels (Figure <xref ref-type="fig" rid="F1">1</xref>A). Measurements of IL-8 peptide indicated an increase at 2&#x02009;h post infection with similar values at 4 and 6&#x02009;h (Figure <xref ref-type="fig" rid="F1">1</xref>B). In the case of IL-10 mRNA, an increase was observed at 4&#x02009;h and remained without a statistical change for up to 6&#x02009;h (Figure <xref ref-type="fig" rid="F1">1</xref>C) while its peptide reached a maximum at 4&#x02009;h (Figure <xref ref-type="fig" rid="F1">1</xref>D). These data indicate that in BEC infected with <italic>S. aureus</italic>, the mechanism responsible for IL-8 expression precedes the mechanism leading to IL-10 expression.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p><italic>Staphylococcus aureus</italic> infection induces interleukin-8 (IL-8) and interleukin-10 (IL-10) expressions in bovine endothelial cells (BECs). BEC controls were left uninfected or infected at a multiplicity of infection of 20&#x02009;CFU/cell <italic>S. aureus</italic> for 2&#x02013;6&#x02009;h. Then, the total RNA was extracted and the relative expression of IL-8 mRNA <bold>(A)</bold> and IL-10 mRNA <bold>(C)</bold> was quantified by reverse transcription and real-time quantitative PCR using the &#x00394;&#x00394;Ct method. Data were normalized in reference to the expression of &#x003B2;-actin. Quantitation of IL-8 <bold>(B)</bold> and IL-10 <bold>(D)</bold> peptides was done by ELISA. Data are presented as the mean&#x02009;&#x000B1;&#x02009;SEM of three independent experiments (SEM; <italic>n</italic>&#x02009;&#x0003D;&#x02009;3 per experiment). &#x0002A;<italic>P</italic>&#x02009;&#x0003C;&#x02009;0.05, &#x0002A;&#x0002A;<italic>P</italic>&#x02009;&#x0003C;&#x02009;0.01 compared to control.</p></caption>
<graphic xlink:href="fimmu-09-00092-g001.tif"/>
</fig>
</sec>
<sec id="S3-2">
<title><italic>S. aureus</italic> Infection Induces a Time-Dependent NF-&#x003BA;B/CREB Phosphorylation and NF-&#x003BA;B Nuclear Translocation</title>
<p>The transcription factors NF-&#x003BA;B and CREB induce IL-8 and IL-10 expressions, respectively (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B34">34</xref>). The transcriptional activation of NF-&#x003BA;B, in response to bacterial ligands, involves the phosphorylation of p65 subunit at Ser536 and its translocation to the nucleus. These events usually take place in the first 15&#x02013;40&#x02009;min after cell stimulation with different ligands (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B36">36</xref>). We observed that the phosphorylation of p65 at Ser536 reached a maximum level at 40&#x02009;min after bacterial challenge followed by a gradual reduction as compared to uninfected control (Figure <xref ref-type="fig" rid="F2">2</xref>A). Several authors have demonstrated that CREB is transcriptionally activated by phosphorylation at Ser133 in response to various stimuli (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B38">38</xref>). Accordingly, a significant increase in phospho-CREB at Ser133 at 60&#x02009;min post infection was detected with a maximum observed at longer infection times of 90&#x02013;120&#x02009;min (Figure <xref ref-type="fig" rid="F2">2</xref>B). Interestingly, these longer infection times that we tested to induce an increase in phospho-CREB-Ser133 were the same as those required for NF-&#x003BA;B to become dephosphorylated and inactivated. These results allowed us to select 40 and 120&#x02009;min as the infection times to explore the effects of <italic>S. aureus</italic> infection on NF-&#x003BA;B p65 and CREB, respectively.</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption><p><italic>Staphylococcus aureu</italic>s activates nuclear factor-kappa B (NF-&#x003BA;B) and cAMP response element-binding (CREB) phosphorylation and induces NF-&#x003BA;B nuclear translocation. Bovine endothelial cells were left uninfected (&#x02212;) or infected at a multiplicity of infection of 20&#x02009;CFU/cell of <italic>S. aureus</italic> for 20&#x02013;120&#x02009;min. After infection, the total protein (nuclear&#x02009;&#x0002B;&#x02009;cytoplasmic) of <bold>(A,B)</bold> or nuclear- and cytoplasmic-enriched fractions <bold>(C)</bold> was analyzed by Western blotting to detect the relative abundance of phosphorylated NF-&#x003BA;B p65 at Ser536 <bold>(A)</bold>, phosphorylated CREB at Ser133 <bold>(B)</bold>, or NF-&#x003BA;B p65 <bold>(C)</bold>. The detection of total unphosphorylated NF-&#x003BA;B p65 <bold>(A)</bold>, total unphosphorylated CREB <bold>(B)</bold>, and &#x003B2;-actin <bold>(A,B)</bold> was performed to ensure equal protein loading. GAPDH and Laminin A/C were detected as protein markers to ensure equal protein loading for cytoplasmic- and nuclear-enriched fractions, respectively <bold>(C)</bold>. Error bars in graphs A and B represent the mean&#x02009;&#x000B1;&#x02009;SEM (<italic>n</italic>&#x02009;&#x0003D;&#x02009;3) of densitometric values. &#x0002A;<italic>P</italic>&#x02009;&#x0003C;&#x02009;0.05, &#x0002A;&#x0002A;<italic>P</italic>&#x02009;&#x0003C;&#x02009;0.01 referred to the uninfected control value.</p></caption>
<graphic xlink:href="fimmu-09-00092-g002.tif"/>
</fig>
<p>The transcription of NF-&#x003BA;B-specific target genes involves its translocation from the cytoplasm to the nucleus. To evaluate NF-&#x003BA;B nuclear translocation, we infected BEC with <italic>S. aureus</italic> at 40 and 120&#x02009;min and detected the relative abundance of NF-&#x003BA;B p65 subunit present in the nucleus or cytosol by Western blotting. The NF-&#x003BA;B p65 subunit was detected in the nuclear fraction after 40&#x02009;min of infection, whereas at 120&#x02009;min, we could not observe it (Figure <xref ref-type="fig" rid="F2">2</xref>C). These indicate that NF-&#x003BA;B phosphorylation and nuclear translocation are processes that take place in the initial phase of infection and precede CREB activation.</p>
</sec>
<sec id="S3-3">
<title>GSK3&#x003B1;/&#x003B2; Inhibition Favors CREB Phosphorylation at Ser133 in BEC Infected with <italic>S. aureus</italic></title>
<p>GSK3&#x003B1; and GSK3&#x003B2; are constitutive active enzymes that regulate the activity of several transcription factors (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B39">39</xref>). We have previously reported that PI3K/Akt-signaling pathway leads to the phosphorylation of GSK3&#x003B1; at Ser21 and GSK3&#x003B2; at Ser9 in <italic>S. aureus</italic> internalization by BEC (<xref ref-type="bibr" rid="B18">18</xref>). However, the role of each isoform in cytokine regulation was not evaluated. Therefore, we decided to investigate the contribution of GSK3&#x003B1; and GSK3&#x003B2; to the regulation of NF-&#x003BA;B and CREB activation in BEC infected with <italic>S. aureus</italic>. The time course of BEC infected with <italic>S. aureus</italic> showed that the phosphorylation of GSK3&#x003B1; (Ser21) and GSK3&#x003B2; (Ser9) increased significantly after 40&#x02009;min of infection (Figures <xref ref-type="fig" rid="F3">3</xref>A,B), GSK3&#x003B1; phosphorylation (&#x0007E;8-fold compared with control) being higher than GSK3&#x003B2; (&#x0007E;2.5-fold compared with control). Interestingly, under basal conditions, BEC phosphorylation of GSK3&#x003B1; Ser21 is barely detected. Other authors have reported similar results about GSK3 relative phosphorylation under basal conditions in different cell types (<xref ref-type="bibr" rid="B40">40</xref>&#x02013;<xref ref-type="bibr" rid="B43">43</xref>).</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption><p><italic>Staphylococcus aureus</italic> inactivates glycogen synthase kinase 3 (GSK3&#x003B1;) and GSK3&#x003B2; by phosphorylation at Ser21 and Ser9. Bovine endothelial cells were left uninfected (&#x02212;) or infected at a multiplicity of infection of 20&#x02009;CFU/cell of <italic>S. aureus</italic> for 20&#x02013;120&#x02009;min <bold>(A,B)</bold> or 20&#x02013;60&#x02009;min <bold>(C)</bold>. The relative abundance of phosphorylated GSK3&#x003B1; at Ser21 <bold>(A)</bold>, GSK3&#x003B2; at Ser9 <bold>(B)</bold>, and glycogen synthase at Ser641 <bold>(C)</bold> was evaluated by Western blotting. The detection of total GSK3&#x003B1;, GSK3&#x003B2;, and &#x003B2;-actin was done to ensure equal protein loading. Error bars in graphs A&#x02013;C are presented as the mean&#x02009;&#x000B1;&#x02009;SEM of three independent experiments (SEM; <italic>n</italic>&#x02009;&#x0003D;&#x02009;3 per experiment). &#x0002A;<italic>P</italic>&#x02009;&#x0003C;&#x02009;0.05, &#x0002A;&#x0002A;<italic>P</italic>&#x02009;&#x0003C;&#x02009;0.01 as compared to control.</p></caption>
<graphic xlink:href="fimmu-09-00092-g003.tif"/>
</fig>
<p>Next, we analyzed whether the increase in the relative abundance of phosphorylated GSK3&#x003B1; and GSK3&#x003B2; isoforms correlated with a decrease in the phosphorylation of glycogen synthase at Ser641 in BEC infected with <italic>S. aureus</italic>. A marked reduction of GSK3&#x003B1;/&#x003B2; kinase activity from 60 to 120&#x02009;min post infection led to a gradual decrease in the relative abundance of phosphorylated glycogen synthase at Ser641 (Figure <xref ref-type="fig" rid="F3">3</xref>C). To further explore if GSK3&#x003B1;/&#x003B2; was associated with NF-&#x003BA;B p65 phosphorylation at Ser536, BECs were pretreated with SB to inhibit GSK3&#x003B1;/&#x003B2; activity before infection for 40 and 120&#x02009;min. The inhibition of GSK3&#x003B1;/&#x003B2; with SB did not reduce the relative abundance of NF-&#x003BA;B p65 phosphorylated at Ser536 (Figure <xref ref-type="fig" rid="F4">4</xref>A, upper panel). In contrast to NF-&#x003BA;B, CREB phosphorylation was affected by the inhibition of GSK3&#x003B1;/&#x003B2; activity, because in <italic>S. aureus-</italic>infected cells, SB induced a substantial increase in the relative abundance of phospho-CREB-Ser133 compared to infected cells at 40&#x02009;min (Figure <xref ref-type="fig" rid="F4">4</xref>A, middle panel). Interestingly, at 120&#x02009;min, SB did not induce a greater increase in phospho-CREB-Ser133 compared to infected cells, indicating that the maximal increase of phospho-CREB-Ser133 in SB-pretreated cells peaked at 40&#x02009;min post infection. Because these observations showed that GSK3 inhibition accelerated the phosphorylation of CREB-Ser133, we tested the relative abundance of p65 and CREB phosphorylation in BEC treated with Akt-IV, an Akt inhibitor. We observed that Akt inhibition did not affect NF-&#x003BA;B p65 phosphorylation level at 40&#x02009;min of infection; however, at 120&#x02009;min, a slight increase in phospho-p65 was observed, suggesting that GSK3&#x003B1;/&#x003B2; activity promotes NF-&#x003BA;B phosphorylation at later stages of infection (Figure <xref ref-type="fig" rid="F4">4</xref>B, upper panel). Akt inhibition completely abolished CREB phosphorylation, indicating that the activated state of GSK3&#x003B1;/&#x003B2; inhibits phospho-CREB-Ser133 increase (Figure <xref ref-type="fig" rid="F4">4</xref>B, middle panel). Finally, the nuclear accumulation of NF-&#x003BA;B p65 was not affected by GSK3&#x003B1;/&#x003B2; inhibition with SB (Figure <xref ref-type="fig" rid="F4">4</xref>C).</p>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption><p>The constitutive activity of glycogen synthase kinase 3 (GSK3&#x003B1;/&#x003B2;) isoforms regulates nuclear factor-kappa B (NF-&#x003BA;B) and cAMP response element-binding (CREB) activity. Bovine endothelial cells (BECs) were left untreated and uninfected (&#x02212;) or pretreated with the GSK3&#x003B1;/&#x003B2; inhibitor SB216763 (10&#x02009;&#x000B5;M) <bold>(A)</bold> or the Akt inhibitor Akt-IV (1&#x02009;&#x000B5;M) <bold>(B)</bold> for 1&#x02009;h before infection at a multiplicity of infection of 20&#x02009;CFU/cell of <italic>Staphylococcus aureus</italic> for the indicated times. Controls pretreated with the inhibitors alone but not infected were also included. After infection, the relative abundance of phosphorylated forms of NF-&#x003BA;B p65 at Ser536 and CREB at Ser133 was detected by Western blotting. Unphosphorylated NF-&#x003BA;B p65 and CREB, and GAPDH were detected to ensure equal protein loading. <bold>(C)</bold> BECs were left untreated and uninfected (&#x02212;) or pretreated with the GSK3&#x003B1;/&#x003B2; inhibitor SB216763 (10&#x02009;&#x000B5;M) for 1&#x02009;h before infection with 20&#x02009;CFU/cell of <italic>S. aureus</italic> for the indicated time. After infection, nuclear- and cytoplasmic-enriched fractions were obtained, and unphosphorylated NF-&#x003BA;B p65 was detected. GAPDH and Laminin A/C were detected as protein markers to ensure equal protein loading for cytoplasmic- and nuclear-enriched fractions, respectively. Blots are representative of three independent experiments.</p></caption>
<graphic xlink:href="fimmu-09-00092-g004.tif"/>
</fig>
<p>To confirm that GSK3&#x003B1;/&#x003B2; activity interferes with CREB phosphorylation at Ser133, the genes of each GSK3 isoform were siRNA-silenced for 120&#x02009;h. After this period, we infected BEC with <italic>S. aureus</italic> for 40&#x02009;min, a time in which GSK3&#x003B1;/&#x003B2; is still active and CREB phosphorylation was barely higher than the uninfected control (Figure <xref ref-type="fig" rid="F2">2</xref>B). GSK3&#x003B1;/&#x003B2; gene silencing was about 60&#x02013;70% for GSK3&#x003B1; and 50&#x02013;60% for GSK3&#x003B2; (Figure <xref ref-type="fig" rid="F5">5</xref>A), demonstrating the efficiency of the siRNA interference technique. Under these conditions, phospho-CREB-Ser133 showed a marked increase in GSK3&#x003B1;/&#x003B2;-silenced cells, compared to non-transfected or control vector cells (Figure <xref ref-type="fig" rid="F5">5</xref>B). These data demonstrate that (1) NF-&#x003BA;B p65 phosphorylation at Ser536 and its nuclear translocation are not directly affected by GSK3&#x003B1;/&#x003B2; activity, (2) GSK3&#x003B1;/&#x003B2; activity directly affects CREB phosphorylation at Ser133, and (3) Akt plays a major role in CREB phosphorylation.</p>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption><p>The glycogen synthase kinase 3 (GSK3&#x003B1;/&#x003B2;) isoforms activity inhibits cAMP response element-binding (CREB) phosphorylation at Ser133. Bovine endothelial cells (BECs) were left with medium only or transfected for 120&#x02009;h with PLKO.1 vector containing siRNA sequences to silence the expression of GSK3&#x003B1; and GSK3&#x003B2; genes or with PLKO.1 control vector. <bold>(A)</bold> Unphosphorylated GSK3&#x003B1;/&#x003B2; was detected to check for protein loading. Error bars in graph represent the mean&#x02009;&#x000B1;&#x02009;SEM (<italic>n</italic>&#x02009;&#x0003D;&#x02009;3) of three independent experiments. &#x0002A;<italic>P</italic>&#x02009;&#x0003C;&#x02009;0.05, referred to the untransfected control. <bold>(B)</bold> BECs were infected with 20&#x02009;CFU/cell of <italic>Staphylococcus aureus</italic> for 40&#x02009;min. After infection, the relative abundance of phosphorylated CREB at Ser133 was analyzed by Western blotting. Unphosphorylated CREB and GAPDH were detected to ensure equal protein loading. Error bars in graph represent the mean&#x02009;&#x000B1;&#x02009;SEM (<italic>n</italic>&#x02009;&#x0003D;&#x02009;3) of three independent experiments. &#x0002A;<italic>P</italic>&#x02009;&#x0003C;&#x02009;0.05, &#x0002A;&#x0002A;<italic>P</italic>&#x02009;&#x0003C;&#x02009;0.001 compared to control.</p></caption>
<graphic xlink:href="fimmu-09-00092-g005.tif"/>
</fig>
</sec>
<sec id="S3-4">
<title>GSK3&#x003B1; Activity Regulates the Interaction between CBP and NF-&#x003BA;B or CREB</title>
<p>A critical step in the transcriptional regulation mediated by NF-&#x003BA;B or CREB is the interaction of each of these transcription factors with the co-activator CBP. NF-&#x003BA;B and CREB compete for the limiting amounts of CBP to form a complex in the nucleus (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B44">44</xref>). To test whether GSK3&#x003B1;/&#x003B2; activity was necessary for NF-&#x003BA;B-CBP or CREB-CBP complex formation in BEC infected with <italic>S. aureus</italic>, we carried out co-IP assays. When BECs were pre-incubated with SB and infected with <italic>S. aureus</italic> for 40&#x02009;min, IP of CBP showed a marked reduction of the NF-&#x003BA;B-CBP interaction and a strong increase of the CREB-CBP complex (Figure <xref ref-type="fig" rid="F6">6</xref>A). Accordingly, the inhibition of Akt with Akt-IV (GSK3&#x003B1;/&#x003B2; remains active under this condition) favored NF-&#x003BA;B, but not CREB, interaction with CBP. The inhibition of GSK3&#x003B1;/&#x003B2; with SB at 40&#x02009;min or control without SB at 120&#x02009;min led to an increase in CREB-CBP interaction (Figure <xref ref-type="fig" rid="F6">6</xref>B). Moreover, at 120&#x02009;min post infection, the Akt inhibition favored the interaction of NF-&#x003BA;B with CBP (Figure <xref ref-type="fig" rid="F6">6</xref>B). These data suggest that an initial stage of infection GSK3&#x003B1;/&#x003B2; activity indirectly favors NF-&#x003BA;B-CBP complex formation but not CREB-CBP interaction, whereas at later stages of infection, when GSK3&#x003B1;/&#x003B2; loses its kinase activity, the opposite occurs.</p>
<fig id="F6" position="float">
<label>Figure 6</label>
<caption><p>The glycogen synthase kinase 3 (GSK3&#x003B1;/&#x003B2;) isoforms regulate the interaction of nuclear factor-kappa B (NF-&#x003BA;B) and cAMP response element binding (CREB) with the transcriptional co-activator CREB-binding protein (CBP). <bold>(A,B)</bold> Cells were left uninfected and untreated (&#x02212;) or pretreated with the GSK3&#x003B1;/&#x003B2; inhibitor SB216763 (10&#x02009;&#x000B5;M) or the Akt inhibitor Akt-IV (1&#x02009;&#x000B5;M) for 1&#x02009;h and infected with 20&#x02009;CFU/cell of <italic>Staphylococcus aureus</italic> for 40 <bold>(A)</bold> or 120&#x02009;min <bold>(B)</bold>. The total protein was extracted (input fraction) for immunoprecipitation (IP) of CBP. Eluates obtained were then used to detect (IB) NF-&#x003BA;B or CREB by Western blotting. A negative control with an iso-type IgG control was also included. NF-&#x003BA;B and CREB were detected in the input fractions to ensure equal protein loading. <bold>(C,D)</bold> Cells were transfected with plasmids containing siRNA sequences against GSK3&#x003B1;, GSK3&#x003B2;, or with control vector as indicated for 5&#x02009;days. Then, siRNA of GSK3 isoforms was evaluated by Western blotting. <bold>(D)</bold> GSK3&#x003B1;/&#x003B2;-silenced cells were infected with <italic>S. aureus</italic> for 120&#x02009;min, and then CBP protein was immunoprecipitated from cell lysates; NF-&#x003BA;B and CREB proteins were detected in the CBP immunoprecipitates by Western blotting. IgG control was included and the total CREB and NF-&#x003BA;B in input cell lysates are also shown.</p></caption>
<graphic xlink:href="fimmu-09-00092-g006.tif"/>
</fig>
<p>To identify which GSK3 isoform was predominantly affecting CREB-CBP or NF-&#x003BA;B-CBP complex formation, we performed an siRNA-silencing assay to independently reduce the expression of each isoform (Figure <xref ref-type="fig" rid="F6">6</xref>C). After infection of BEC with <italic>S. aureus</italic> for 40&#x02009;min, we immunoprecipitated CBP, and CREB or NF-&#x003BA;B was immunodetected in the precipitated fraction. In <italic>S. aureus</italic>-infected cells, GSK3&#x003B1; was the primary isoform that affected CREB-CBP interaction, because in either GSK3&#x003B1; or GSK3&#x003B1;/&#x003B2;-silenced cells, a stronger interaction between CREB and CBP was observed compared to the amount of CREB-CBP complex seen in GSK3&#x003B2;-silenced cells (Figure <xref ref-type="fig" rid="F6">6</xref>D). This preferential association found between CREB and CBP in GSK3&#x003B1;-silenced cells repressed NF-&#x003BA;B-CBP interaction because of the reduced amount of NF-&#x003BA;B-CBP complex in these cells compared to the infected controls or the GSK3&#x003B2;-silenced cells.</p>
</sec>
<sec id="S3-5">
<title>NF-&#x003BA;B and CREB Regulate IL-8 and IL-10 Expressions in BEC Infected with <italic>S. aureus</italic></title>
<p>To evaluate the role of NF-&#x003BA;B on IL-8 and IL-10 expressions, we incubated BEC with 20&#x02009;&#x000B5;M Parthenolide, an NF-&#x003BA;B inhibitor, for 1&#x02009;h before infection. Under these conditions, a reduced IL-8 expression was observed at 2&#x02009;h post infection (Figure <xref ref-type="fig" rid="F7">7</xref>A), whereas an increased IL-10 expression was detected at 6&#x02009;h post infection (Figure <xref ref-type="fig" rid="F7">7</xref>B), indicating that NF-&#x003BA;B activity causes a slight inhibition of IL-10 expression in BEC infected with <italic>S. aureus</italic>. Then, we evaluated the role of CREB on IL-8 and IL-10 expressions by transfecting BEC with a plasmid containing a CREB-Ser133Ala-dominant-negative mutant (DN-CREB-Ser133Ala) (Figure S1 in Supplementary Material). At 2&#x02009;h post infection, the DN-CREB-Ser133Ala-expressing cells showed an increased expression of IL-8 (Figure <xref ref-type="fig" rid="F7">7</xref>C). By contrast, at 6&#x02009;h post infection, the DN-CREB-Ser133Ala-expressing cells showed a significant reduction of IL-10 expression (Figure <xref ref-type="fig" rid="F7">7</xref>D). These results confirm that NF-&#x003BA;B and CREB compete for binding CBP and that they are essential for IL-8 and IL-10 expressions in BEC infected with <italic>S. aureus</italic>.</p>
<fig id="F7" position="float">
<label>Figure 7</label>
<caption><p><italic>Staphylococcus aureus</italic>-induced expression of interleukin-8 (IL-8) and interleukin-10 (IL-10) is regulated by nuclear factor-kappa B (NF-&#x003BA;B) and cAMP response element binding (CREB). <bold>(A,B)</bold> Bovine endothelial cells (BECs) were left uninfected and untreated (&#x02212;) or pretreated with the NF-&#x003BA;B inhibitor Parthenolide (20&#x02009;&#x000B5;M) for 1&#x02009;h and then infected with 20&#x02009;CFU/cell of <italic>S. aureus</italic> for 6&#x02009;h. A control group pretreated with 20&#x02009;&#x000B5;M of Parthenolide was also included. <bold>(C,D)</bold> BECs were treated with a medium or transfected with a plasmid containing the dominant-negative mutant of CREB-S133A (DN-CREB) or the control plasmid pCF (control vector) for 48&#x02009;h and then infected with 20&#x02009;CFU/cell of <italic>S. aureus</italic> for 6&#x02009;h. Control-uninfected cells transfected with the DN-CREB or plasmid pCF were included. After infection, the conditioned media were collected in ice-cold tubes and kept frozen at &#x02212;80&#x000B0;C. Quantitation of IL-8 and IL-10 was done by ELISA, according to the manufacturer&#x02019;s instructions. Data represent the mean&#x02009;&#x000B1;&#x02009;SEM (<italic>n</italic>&#x02009;&#x0003D;&#x02009;3) from two independent experiments. &#x0002A;<italic>P</italic>&#x02009;&#x0003C;&#x02009;0.05, &#x0002A;&#x0002A;<italic>P</italic>&#x02009;&#x0003C;&#x02009;0.01 as compared to control.</p></caption>
<graphic xlink:href="fimmu-09-00092-g007.tif"/>
</fig>
</sec>
<sec id="S3-6">
<title>GSK3&#x003B1;/&#x003B2; Activity Regulates IL-8 and IL-10 Expressions in BEC Infected with <italic>S. aureus</italic></title>
<p>To investigate whether GSK3&#x003B1;/&#x003B2; activity influences NF-&#x003BA;B and CREB transcriptional activity and this, in turn, regulates IL-8 and IL-10 expressions, BECs were pre-incubated with SB or Akt-IV for 1&#x02009;h. After infection with <italic>S. aureus</italic> for 6&#x02009;h, the IL-8 and IL-10 peptides were quantitated by ELISA. We observed a reduction in IL-8 peptide compared to the infected control cells in the presence of SB, whereas in BEC treated with Akt-IV, a condition in which GSK3&#x003B1;/&#x003B2; isoforms are active, the IL-8 expression was higher after 6&#x02009;h as compared to SB treated or infected control cells (Figure <xref ref-type="fig" rid="F8">8</xref>A). The expression of IL-10 increased when BECs were incubated with SB at 6&#x02009;h post infection, whereas in the presence of Akt-IV, no change in IL-10 peptide compared to control was observed, indicating that active Akt (inactive GSK3&#x003B1;/&#x003B2;) was required to induce IL-10 synthesis (Figure <xref ref-type="fig" rid="F8">8</xref>B). These data suggest that GSK3&#x003B1;/&#x003B2; activity promotes IL-8 peptide synthesis during <italic>S. aureus</italic> infection and that the loss of GSK3&#x003B1;/&#x003B2; activity leads to a reduction of IL-8 and an increase in IL-10 expression.</p>
<fig id="F8" position="float">
<label>Figure 8</label>
<caption><p>The glycogen synthase kinase 3 (GSK3&#x003B1;/&#x003B2;) activity controls <italic>Staphylococcus aureus</italic>-induced expression of interleukin-8 (IL-8) and interleukin-10 (IL-10). <bold>(A,B)</bold> Bovine endothelial cells (BECs) were left uninfected and untreated (&#x02212;) or pretreated with GSK3&#x003B1;/&#x003B2; inhibitor SB216763 (10&#x02009;&#x000B5;M) or Akt inhibitor Akt-IV (1&#x02009;&#x000B5;M) for 1&#x02009;h and then infected with 20&#x02009;CFU/cell of <italic>S. aureus</italic> for 6&#x02009;h. A control pretreated with SB216763 (10&#x02009;&#x000B5;M) or Akt-IV (1&#x02009;&#x000B5;M) was also included. After infection, the conditioned media were collected in ice-cold tubes and kept frozen at &#x02212;80&#x000B0;C. The quantitation of IL-8 and IL-10 was done by ELISA, according to the manufacturer&#x02019;s instructions. Data represent the mean&#x02009;&#x000B1;&#x02009;SEM (<italic>n</italic>&#x02009;&#x0003D;&#x02009;3) from two independent experiments. &#x0002A;<italic>P</italic>&#x02009;&#x0003C;&#x02009;0.05, &#x0002A;&#x0002A;<italic>P</italic>&#x02009;&#x0003C;&#x02009;0.01 compared to control.</p></caption>
<graphic xlink:href="fimmu-09-00092-g008.tif"/>
</fig>
</sec>
<sec id="S3-7">
<title>GSK3&#x003B1; Activity Is the Main Isoform That Regulates IL-8 and IL-10 Expressions in BEC Infected with <italic>S. aureus</italic></title>
<p>We have presented evidence that in BEC infected with <italic>S. aureus</italic>, (1) GSK3&#x003B1; is highly phosphorylated, (2) GSK3&#x003B1; promotes CREB-CBP interaction, which is essential for IL-10 expression, and (3) GSK3&#x003B1; represses NF-&#x003BA;B-CBP interaction, which is critically indispensable for IL-8 expression. To confirm that GSK3&#x003B1; is the main isoform regulating these processes, we performed an siRNA-gene-silencing assay to reduce the expression of each GSK3 isoform in BEC infected with <italic>S. aureus</italic> for 6&#x02009;h followed by the detection of IL-8 and IL-10 peptides by ELISA. We observed that GSK3&#x003B1; was the main isoform that regulates IL-8 and IL-10 expressions because GSK3&#x003B1; or GSK3&#x003B1;/&#x003B2;-silenced cells showed a stronger reduction of IL-8 expression and an increased IL-10 expression compared to GSK3&#x003B2;-silenced or control-infected cells (Figures <xref ref-type="fig" rid="F9">9</xref>A,B). Evidence of GSK3&#x003B1; and GSK3&#x003B2; gene-silencing efficiency is shown in Figure <xref ref-type="fig" rid="F9">9</xref>C. These data demonstrate that GSK3&#x003B1; is the primary isoform that regulates the expression of IL-8 and IL-10 in BEC infected with <italic>S. aureus</italic>.</p>
<fig id="F9" position="float">
<label>Figure 9</label>
<caption><p>The glycogen synthase kinase 3 (GSK3&#x003B1;) is the primary isoform that regulates interleukin-8 (IL-8) and interleukin-10 (IL-10) expression in bovine endothelial cell infected with <italic>Staphylococcus aureus</italic>. <bold>(A&#x02013;C)</bold> Cells were left untransfected or transfected with plasmids containing siRNA against GSK3&#x003B1; or GSK3&#x003B2; or empty vector as indicated for 5&#x02009;days. Then, cells were infected with <italic>S. aureus</italic> at a multiplicity of infection of 20 UFC/cell for 6&#x02009;h or with a medium alone, and IL-8 <bold>(A)</bold> and IL-10 <bold>(B)</bold> peptide expressions were evaluated by ELISA technique. Controls uninfected/untransfected and transfected/uninfected were also included. <bold>(C)</bold> A Western blot to represent the effectiveness of silencing technique is also shown. Data represent mean&#x02009;&#x000B1;&#x02009;SEM from results obtained in two independent experiments measured by duplicate. &#x0002A;<italic>P</italic>&#x02009;&#x0003C;&#x02009;0.05, &#x0002A;&#x0002A;<italic>P</italic>&#x02009;&#x0003C;&#x02009;0.01 compared to control.</p></caption>
<graphic xlink:href="fimmu-09-00092-g009.tif"/>
</fig>
</sec>
</sec>
<sec id="S4" sec-type="discussion">
<title>Discussion</title>
<p>Several reports have described an inhibition of IL-8 expression after a &#x0201C;<italic>short-live</italic>&#x0201D; temporary increase when <italic>S. aureus</italic> infects a variety of cells (<xref ref-type="bibr" rid="B4">4</xref>&#x02013;<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B45">45</xref>). For example, in conjunctiva epithelial cells, a significant increase in IL-8 mRNA was detected at 3&#x02009;h post infection and a marked reduction after 4&#x02009;h, an effect attributed to phenol-soluble modulins from <italic>S. aureus</italic> (<xref ref-type="bibr" rid="B45">45</xref>). Also, bovine mammary epithelial cells infected with <italic>S. aureus</italic> expressed IL-8 at initial stages (8&#x02009;h), but at longer infection times (24&#x02013;48&#x02009;h), no increase was detected (<xref ref-type="bibr" rid="B46">46</xref>). In neutrophils, <italic>S. aureus</italic> strain USA300 inhibited NF-&#x003BA;B-dependent IL-8 expression and promoted cell death (<xref ref-type="bibr" rid="B6">6</xref>). Interestingly, in this case, the inhibition of NF-&#x003BA;B was related to the <italic>S. aureus</italic> SaeR/S system regulation, which is important for phenol-soluble modulins expression (<xref ref-type="bibr" rid="B47">47</xref>). <italic>S. aureus</italic> infections also promoted IL-10 expression, a cytokine associated with bacterial survival and immune-tolerogenic response (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B48">48</xref>). Interestingly, as it is the case for IL-8, the phenol-soluble modulins were also involved in IL-10 expression by dendritic cells (<xref ref-type="bibr" rid="B49">49</xref>). The expression of IL-6 and TNF-&#x003B1; at initial stages of infection and IL-10 at longer stages was also detected in the serum of mice infected with <italic>S. aureus</italic> (<xref ref-type="bibr" rid="B50">50</xref>); however, in all these reports, a molecular mechanism was not described. In this work, we have presented experimental evidence indicating that BEC infected with <italic>S. aureus</italic> activates NF-&#x003BA;B and expresses IL-8 at initial stages of infection (2&#x02009;h) and activates CREB and IL-10 expression at later stages (6&#x02009;h). Apparently, this molecular switch from pro-inflammatory to an anti-inflammatory cytokine expression is mainly regulated by the activity state of GSK3&#x003B1;. We have also shown that GSK3&#x003B1; regulates the balance of cytokines expression by modulating the activity of NF-&#x003BA;B and CREB in a similar way as GSK3&#x003B2; (<xref ref-type="bibr" rid="B14">14</xref>).</p>
<p>For more than 10 years, GSK3&#x003B2; has been considered the main isoform responsible for the regulation of the inflammatory response (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B51">51</xref>). Various studies have confirmed that GSK3&#x003B2; regulates the response to infections caused by Gram (&#x02212;)/(&#x0002B;) bacteria like <italic>Helicobacter pylori, Francisella tularensis</italic>, and <italic>Mycobacterium</italic> sp. (<xref ref-type="bibr" rid="B52">52</xref>&#x02013;<xref ref-type="bibr" rid="B54">54</xref>). Although several reports have provided evidence that GSK3&#x003B1; is the main isoform expressed in various cell types, shares the same substrates, and is also inactivated in similar ways as GSK3&#x003B2; (<xref ref-type="bibr" rid="B55">55</xref>&#x02013;<xref ref-type="bibr" rid="B57">57</xref>), no correlation of GSK3&#x003B1; activity on the regulation of the inflammatory response after bacterial stimulation has been documented. This lack of information prompted us to explore whether GSK3&#x003B1; may be responsible for the regulation of pro- and anti-inflammatory cytokines expression in BEC infected with <italic>S. aureus</italic>. Data in this work indicate that the relative abundance of phospho-GSK3&#x003B1; was higher than that of phospho-GSK3&#x003B2; during the infection of BEC with viable <italic>S. aureus</italic> (Figures <xref ref-type="fig" rid="F3">3</xref>A,B), as we have previously reported (<xref ref-type="bibr" rid="B18">18</xref>). The predominance of phospho-GSK3&#x003B1; over phospho-GSK3&#x003B2; in our system suggests specific roles for each GSK3 isoform during the inflammatory response triggered by <italic>S. aureus</italic>. At initial stages of infection, a gradually decreasing fraction of GSK3&#x003B1; and in minor proportion GSK3&#x003B2; remains activated, implying an indirect correlation between the amount of GSK3&#x003B1; in its active form and the expression of IL-8. In line with this thought, we found that complete GSK3&#x003B1; inhibition at 120&#x02009;min post infection led to a substantial reduction of the NF-&#x003BA;B-CBP complex compared with the abundance of this complex observed at 40&#x02009;min post infection (Figure <xref ref-type="fig" rid="F6">6</xref>A) and a high increase in CREB-CBP interaction (Figure <xref ref-type="fig" rid="F6">6</xref>B). Furthermore, the IL-8 expression increased and remained at high levels after 6&#x02009;h when Akt was inhibited to avoid GSK3&#x003B1; inhibition (Figure <xref ref-type="fig" rid="F8">8</xref>A). These data indicate that GSK3&#x003B1; activity is required to maintain IL-8 expression at longer infection periods and that GSK3&#x003B1; inhibition was related to a loss of NF-&#x003BA;B transcriptional activity and the activation of CREB.</p>
<p>Another important issue derived from our results is how GSK3&#x003B1; represses the phosphorylation of CREB at Ser133 because GSK3 is unable to phosphorylate CREB in this residue. An intriguing possibility is that GSK3 constitutive activity controls an unidentified CREB kinase. In support of this notion, GSK3&#x003B1; was identified in rat cerebral cortical cells as the responsible isoform that represses CREB transcriptional activity (<xref ref-type="bibr" rid="B58">58</xref>) and reduces the affinity of Akt against different substrates by phosphorylating Akt at Thr312 (<xref ref-type="bibr" rid="B59">59</xref>). In addition, siRNA silencing of the GSK3&#x003B1; gene expression enhanced phospho-CREB-Ser133 and CRE transcriptional activity (<xref ref-type="bibr" rid="B59">59</xref>). In agreement, our evidence shows that Akt activity was critical to increase phospho-CREB-Ser133, which suggests that GSK3&#x003B1; inhibition promotes CREB phosphorylation at Ser133 by an Akt-dependent mechanism. Importantly, GSK3&#x003B1; is now known as a novel CREB-target gene that promotes the viability of cancer cells and NF-&#x003BA;B-dependent gene transcription of TERT (<xref ref-type="bibr" rid="B60">60</xref>), indicating a reciprocal regulation between CREB and GSK3&#x003B1;. Further investigation on the mechanisms of this reciprocal regulation deserves consideration in the context of the bacteria-activated inflammatory response.</p>
<p>In conclusion, during the first 60&#x02009;min of BEC infection by <italic>S. aureus</italic>, GSK3&#x003B1; activity maintains its inhibitory influence on CREB phosphorylation at Ser133, limiting the formation of CREB-CBP complex and leaving CBP free to interact with NF-&#x003BA;B. This mechanism promotes a pro-inflammatory environment because of the IL-8 expression. If the stimulus persists for 120&#x02009;min, GSK3&#x003B1;/&#x003B2; becomes fully phosphorylated by Akt, which indirectly inhibits NF-&#x003BA;B transcriptional activity. The inhibition of GSK3&#x003B1;, and in minor proportion GSK3&#x003B2;, causes an increase in phospho-CREB-Ser133, which is now able to compete for CBP to form the transcriptionally active CREB-CBP complex. Such a molecular switch markedly reduces the expression of pro-inflammatory chemokine IL-8 and stimulates the expression of immune-suppressive and -tolerogenic cytokine IL-10. More experiments will be undoubtedly needed to clarify the specific mechanistic details of the differential actions of GSK3&#x003B1; on the regulation of the inflammatory response caused by pathogenic bacteria.</p>
</sec>
<sec id="S5" sec-type="author-contributor">
<title>Author Contributions</title>
<p>OS-G contributed with ideas of experimental design, performed 90% of the experiments, analyzed results, and wrote the first draft; RR-M performed 5% of the experiments; MM-P, performed 5% of the experiments; AB-P, JV-A, and JA-G critical review and corrections of this manuscript; VB-A central idea of the research, wrote this manuscript, and financially supported the research.</p>
</sec>
<sec id="S6">
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<p>This work was supported by the Consejo Nacional de Ciencia y Tecnolog&#x000ED;a (CONACYT-M&#x000E9;xico) grant number 152518 and Coordinaci&#x000F3;n de la Investigaci&#x000F3;n Cient&#x000ED;fica, Universidad Michoacana de San Nicol&#x000E1;s de Hidalgo, to VMB-A. OS-G is a recipient of a doctoral scholarship from CONACYT-M&#x000E9;xico. RR-M was supported by a postdoctoral scholarship from CONACYT-M&#x000E9;xico. MM-P was supported by a master scholarship from CONACYT-M&#x000E9;xico.</p>
</ack>
<sec id="S7" sec-type="supplementary-material">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at <uri xlink:href="http://www.frontiersin.org/articles/10.3389/fimmu.2018.00092/full&#x00023;supplementary-material">http://www.frontiersin.org/articles/10.3389/fimmu.2018.00092/full&#x00023;supplementary-material</uri>.</p>
<supplementary-material xlink:href="Image_1.TIF" id="SM1" mimetype="applicationn/TIF" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oviedo-Boyso</surname> <given-names>J</given-names></name> <name><surname>Valdez-Alarc&#x000F3;n</surname> <given-names>JJ</given-names></name> <name><surname>Cajero-Ju&#x000E1;rez</surname> <given-names>M</given-names></name> <name><surname>Ochoa-Zarzosa</surname> <given-names>A</given-names></name> <name><surname>L&#x000F3;pez-Meza</surname> <given-names>JE</given-names></name> <name><surname>Bravo-Pati&#x000F1;o</surname> <given-names>A</given-names></name> <etal/></person-group> <article-title>Innate immune response of bovine mammary gland to pathogenic bacteria responsible for mastitis</article-title>. <source>J Infect</source> (<year>2007</year>) <volume>54</volume>:<fpage>399</fpage>&#x02013;<lpage>409</lpage>.<pub-id pub-id-type="doi">10.1016/j.jinf.2006.06.010</pub-id><pub-id pub-id-type="pmid">16882453</pub-id></citation></ref>
<ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>HK</given-names></name> <name><surname>Thammavongsa</surname> <given-names>V</given-names></name> <name><surname>Schneewind</surname> <given-names>O</given-names></name> <name><surname>Missiakas</surname> <given-names>D</given-names></name></person-group>. <article-title>Recurrent infections and immune evasion strategies of <italic>Staphylococcus aureus</italic></article-title>. <source>Curr Opin Microbiol</source> (<year>2012</year>) <volume>15</volume>:<fpage>92</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.mib.2011.10.012</pub-id><pub-id pub-id-type="pmid">22088393</pub-id></citation></ref>
<ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Voyich</surname> <given-names>JM</given-names></name> <name><surname>Braughton</surname> <given-names>KR</given-names></name> <name><surname>Sturdevant</surname> <given-names>DE</given-names></name> <name><surname>Whitney</surname> <given-names>AR</given-names></name> <name><surname>Sa&#x000EF;d-Salim</surname> <given-names>B</given-names></name> <name><surname>Porcella</surname> <given-names>SF</given-names></name> <etal/></person-group> <article-title>Insights into mechanisms used by <italic>Staphylococcus aureus</italic> to avoid destruction by human neutrophils</article-title>. <source>J Immunol</source> (<year>2005</year>) <volume>175</volume>:<fpage>3907</fpage>&#x02013;<lpage>19</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.175.6.3907</pub-id><pub-id pub-id-type="pmid">16148137</pub-id></citation></ref>
<ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chekabab</surname> <given-names>SM</given-names></name> <name><surname>Silverman</surname> <given-names>RJ</given-names></name> <name><surname>Lafayette</surname> <given-names>SL</given-names></name> <name><surname>Luo</surname> <given-names>Y</given-names></name> <name><surname>Rousseau</surname> <given-names>S</given-names></name> <name><surname>Nguyen</surname> <given-names>D</given-names></name></person-group>. <article-title><italic>Staphylococcus aureus</italic> inhibits IL-8 responses induced by <italic>Pseudomonas aeruginosa</italic> in airway epithelial cells</article-title>. <source>PLoS One</source> (<year>2015</year>) <volume>10</volume>:<fpage>e0137753</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0137753</pub-id><pub-id pub-id-type="pmid">26360879</pub-id></citation></ref>
<ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tajima</surname> <given-names>A</given-names></name> <name><surname>Seki</surname> <given-names>K</given-names></name> <name><surname>Shinji</surname> <given-names>H</given-names></name> <name><surname>Masuda</surname> <given-names>S</given-names></name></person-group>. <article-title>Inhibition of interleukin-8 production in human endothelial cells by <italic>Staphylococcus aureus</italic> supernatant</article-title>. <source>Clin Exp Immunol</source> (<year>2007</year>) <volume>147</volume>:<fpage>148</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2249.2006.03254.x</pub-id><pub-id pub-id-type="pmid">17177974</pub-id></citation></ref>
<ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zurek</surname> <given-names>OW</given-names></name> <name><surname>Pallister</surname> <given-names>KB</given-names></name> <name><surname>Voyich</surname> <given-names>JM</given-names></name></person-group>. <article-title><italic>Staphylococcus aureus</italic> inhibits neutrophil-derived IL-8 to promote cell death</article-title>. <source>J Infect Dis</source> (<year>2015</year>) <volume>212</volume>:<fpage>934</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1093/infdis/jiv124</pub-id><pub-id pub-id-type="pmid">25722299</pub-id></citation></ref>
<ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tajima</surname> <given-names>A</given-names></name> <name><surname>Iwase</surname> <given-names>T</given-names></name> <name><surname>Shinji</surname> <given-names>H</given-names></name> <name><surname>Seki</surname> <given-names>K</given-names></name> <name><surname>Mizunoe</surname> <given-names>Y</given-names></name></person-group>. <article-title>Inhibition of endothelial interleukin-8 production and neutrophil transmigration by <italic>Staphylococcus aureus</italic> beta-hemolysin</article-title>. <source>Infect Immun</source> (<year>2009</year>) <volume>77</volume>:<fpage>327</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="doi">10.1128/IAI.00748-08</pub-id><pub-id pub-id-type="pmid">18936175</pub-id></citation></ref>
<ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Livaditi</surname> <given-names>O</given-names></name> <name><surname>Kotanidou</surname> <given-names>A</given-names></name> <name><surname>Psarra</surname> <given-names>A</given-names></name> <name><surname>Dimopoulou</surname> <given-names>I</given-names></name> <name><surname>Sotiropoulou</surname> <given-names>C</given-names></name> <name><surname>Augustatou</surname> <given-names>K</given-names></name> <etal/></person-group> <article-title>Neutrophil CD64 expression and serum IL-8: sensitive early markers of severity and outcome in sepsis</article-title>. <source>Cytokine</source> (<year>2006</year>) <volume>36</volume>:<fpage>283</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1016/j.cyto.2007.02.007</pub-id><pub-id pub-id-type="pmid">17368039</pub-id></citation></ref>
<ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirao</surname> <given-names>Y</given-names></name> <name><surname>Kanda</surname> <given-names>T</given-names></name> <name><surname>Aso</surname> <given-names>Y</given-names></name> <name><surname>Mitsuhashi</surname> <given-names>M</given-names></name> <name><surname>Kobayashi</surname> <given-names>I</given-names></name></person-group>. <article-title>Interleukin-8-an early marker for bacterial infection</article-title>. <source>Lab Med</source> (<year>2000</year>) <volume>31</volume>:<fpage>39</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1309/GJ98-JAH8-VQ57-D6N0</pub-id></citation></ref>
<ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heim</surname> <given-names>CE</given-names></name> <name><surname>Vidlak</surname> <given-names>D</given-names></name> <name><surname>Kielian</surname> <given-names>T</given-names></name></person-group>. <article-title>Interleukin-10 production by myeloid-derived suppressor cells contributes to bacterial persistence during <italic>Staphylococcus aureus</italic> orthopedic biofilm infection</article-title>. <source>J Leukoc Biol</source> (<year>2015</year>) <volume>98</volume>:<fpage>1003</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1189/jlb.4VMA0315-125RR</pub-id><pub-id pub-id-type="pmid">26232453</pub-id></citation></ref>
<ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leech</surname> <given-names>JM</given-names></name> <name><surname>Lacey</surname> <given-names>KA</given-names></name> <name><surname>Mulcahy</surname> <given-names>ME</given-names></name> <name><surname>Medina</surname> <given-names>E</given-names></name> <name><surname>McLoughlin</surname> <given-names>RM</given-names></name></person-group>. <article-title>IL-10 plays opposing roles during <italic>Staphylococcus aureus</italic> systemic and localized infections</article-title>. <source>J Immunol</source> (<year>2017</year>) <volume>198</volume>:<fpage>2352</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1601018</pub-id><pub-id pub-id-type="pmid">28167629</pub-id></citation></ref>
<ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akira</surname> <given-names>S</given-names></name> <name><surname>Takeda</surname> <given-names>K</given-names></name></person-group>. <article-title>Toll-like receptor signalling</article-title>. <source>Nat Rev Immunol</source> (<year>2004</year>) <volume>4</volume>:<fpage>499</fpage>&#x02013;<lpage>511</lpage>.<pub-id pub-id-type="doi">10.1038/nri1391</pub-id></citation></ref>
<ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vara</surname> <given-names>J&#x000C1;F</given-names></name> <name><surname>Casado</surname> <given-names>E</given-names></name> <name><surname>de Castro</surname> <given-names>J</given-names></name> <name><surname>Cejas</surname> <given-names>P</given-names></name> <name><surname>Belda-Iniesta</surname> <given-names>C</given-names></name> <name><surname>Gonz&#x000E1;lez-Bar&#x000F3;n</surname> <given-names>M</given-names></name></person-group>. <article-title>PI3K/Akt signalling pathway and cancer</article-title>. <source>Cancer Treat Rev</source> (<year>2004</year>) <volume>30</volume>:<fpage>193</fpage>&#x02013;<lpage>204</lpage>.<pub-id pub-id-type="doi">10.1016/j.ctrv.2003.07.007</pub-id><pub-id pub-id-type="pmid">15023437</pub-id></citation></ref>
<ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname> <given-names>M</given-names></name> <name><surname>Rehani</surname> <given-names>K</given-names></name> <name><surname>Jope</surname> <given-names>RS</given-names></name> <name><surname>Michalek</surname> <given-names>SM</given-names></name></person-group>. <article-title>Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3</article-title>. <source>Nat Immunol</source> (<year>2005</year>) <volume>6</volume>:<fpage>777</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1038/ni1221</pub-id><pub-id pub-id-type="pmid">16007092</pub-id></citation></ref>
<ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cort&#x000E9;s-Vieyra</surname> <given-names>R</given-names></name> <name><surname>Bravo-Pati&#x000F1;o</surname> <given-names>A</given-names></name> <name><surname>Valdez-Alarc&#x000F3;n</surname> <given-names>JJ</given-names></name> <name><surname>Ju&#x000E1;rez</surname> <given-names>MC</given-names></name> <name><surname>Finlay</surname> <given-names>BB</given-names></name> <name><surname>Baizabal-Aguirre</surname> <given-names>VM</given-names></name></person-group>. <article-title>Role of glycogen synthase kinase-3 beta in the inflammatory response caused by bacterial pathogens</article-title>. <source>J Inflamm</source> (<year>2012</year>) <volume>9</volume>:<fpage>23</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1186/1476-9255-9-23</pub-id><pub-id pub-id-type="pmid">22691598</pub-id></citation></ref>
<ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname> <given-names>DA</given-names></name> <name><surname>Alessi</surname> <given-names>DR</given-names></name> <name><surname>Cohen</surname> <given-names>P</given-names></name> <name><surname>Andjelkovich</surname> <given-names>M</given-names></name> <name><surname>Hemmings</surname> <given-names>BA</given-names></name></person-group>. <article-title>Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B</article-title>. <source>Nature</source> (<year>1995</year>) <volume>378</volume>:<fpage>785</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1038/378785a0</pub-id><pub-id pub-id-type="pmid">8524413</pub-id></citation></ref>
<ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beurel</surname> <given-names>E</given-names></name> <name><surname>Grieco</surname> <given-names>SF</given-names></name> <name><surname>Jope</surname> <given-names>RS</given-names></name></person-group>. <article-title>Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases</article-title>. <source>Pharmacol Ther</source> (<year>2015</year>) <volume>148</volume>:<fpage>114</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1016/j.pharmthera.2014.11.016</pub-id><pub-id pub-id-type="pmid">25435019</pub-id></citation></ref>
<ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oviedo-Boyso</surname> <given-names>J</given-names></name> <name><surname>Cort&#x000E9;s-Vieyra</surname> <given-names>R</given-names></name> <name><surname>Huante-Mendoza</surname> <given-names>A</given-names></name> <name><surname>Hong</surname> <given-names>BY</given-names></name> <name><surname>Valdez-Alarc&#x000F3;n</surname> <given-names>JJ</given-names></name> <name><surname>Bravo-Pati&#x000F1;o</surname> <given-names>A</given-names></name> <etal/></person-group> <article-title>The phosphoinositide-3-kinase-Akt signaling pathway is important for <italic>Staphylococcus aureus</italic> internalization by endothelial cells</article-title>. <source>Infect Immun</source> (<year>2011</year>) <volume>79</volume>:<fpage>4569</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="doi">10.1128/IAI.05303-11</pub-id><pub-id pub-id-type="pmid">21844240</pub-id></citation></ref>
<ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cort&#x000E9;s-Vieyra</surname> <given-names>R</given-names></name> <name><surname>Silva-Garc&#x000ED;a</surname> <given-names>O</given-names></name> <name><surname>Oviedo-Boyso</surname> <given-names>J</given-names></name> <name><surname>Huante-Mendoza</surname> <given-names>A</given-names></name> <name><surname>Bravo-Pati&#x000F1;o</surname> <given-names>A</given-names></name> <name><surname>Valdez-Alarc&#x000F3;n</surname> <given-names>JJ</given-names></name> <etal/></person-group> <article-title>The glycogen synthase kinase 3&#x003B1; and &#x003B2; isoforms differentially regulates interleukin-12p40 expression in endothelial cells stimulated with peptidoglycan from <italic>Staphylococcus aureus</italic></article-title>. <source>PLoS One</source> (<year>2015</year>) <volume>10</volume>:<fpage>e0132867</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0132867</pub-id></citation></ref>
<ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoeflich</surname> <given-names>KP</given-names></name> <name><surname>Luo</surname> <given-names>J</given-names></name> <name><surname>Rubie</surname> <given-names>EA</given-names></name> <name><surname>Tsao</surname> <given-names>M-S</given-names></name> <name><surname>Jin</surname> <given-names>O</given-names></name> <name><surname>Woodgett</surname> <given-names>JR</given-names></name></person-group>. <article-title>Requirement for glycogen synthase kinase-3&#x003B2; in cell survival and NF-&#x003BA;B activation</article-title>. <source>Nature</source> (<year>2000</year>) <volume>406</volume>:<fpage>86</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1038/35017574</pub-id></citation></ref>
<ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McAlpine</surname> <given-names>CS</given-names></name> <name><surname>Huang</surname> <given-names>A</given-names></name> <name><surname>Emdin</surname> <given-names>A</given-names></name> <name><surname>Banko</surname> <given-names>NS</given-names></name> <name><surname>Beriault</surname> <given-names>DR</given-names></name> <name><surname>Shi</surname> <given-names>Y</given-names></name> <etal/></person-group> <article-title>Deletion of myeloid GSK3&#x003B1; attenuates atherosclerosis and promotes an M2 macrophage phenotype</article-title>. <source>Arterioscler Thromb Vasc Biol</source> (<year>2015</year>) <volume>5</volume>:<fpage>1113</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1161/ATVBAHA.115.305438</pub-id><pub-id pub-id-type="pmid">25767272</pub-id></citation></ref>
<ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Woodgett</surname> <given-names>JR</given-names></name></person-group>. <article-title>Molecular cloning and expression of glycogen synthase kinase-3/factor A</article-title>. <source>EMBO J</source> (<year>1990</year>) <volume>9</volume>:<fpage>2431</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">2164470</pub-id></citation></ref>
<ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Banko</surname> <given-names>NS</given-names></name> <name><surname>McAlpine</surname> <given-names>CS</given-names></name> <name><surname>Venegas-Pino</surname> <given-names>DE</given-names></name> <name><surname>Raja</surname> <given-names>P</given-names></name> <name><surname>Shi</surname> <given-names>Y</given-names></name> <name><surname>Khan</surname> <given-names>MI</given-names></name> <etal/></person-group> <article-title>Glycogen synthase kinase 3&#x003B1; deficiency attenuates atherosclerosis and hepatic steatosis in high fat diet-fed low density lipoprotein receptor-deficient mice</article-title>. <source>Am J Pathol</source> (<year>2014</year>) <volume>184</volume>:<fpage>3394</fpage>&#x02013;<lpage>404</lpage>.<pub-id pub-id-type="doi">10.1016/j.ajpath.2014.07.028</pub-id></citation></ref>
<ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Q</given-names></name> <name><surname>Zhou</surname> <given-names>Y</given-names></name> <name><surname>Evers</surname> <given-names>BM</given-names></name></person-group>. <article-title>Neurotensin phosphorylates GSK-3&#x003B1;/&#x003B2; through the activation of PKC in human colon cancer cells</article-title>. <source>Neoplasia</source> (<year>2006</year>) <volume>8</volume>:<fpage>781</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1593/neo.06259</pub-id></citation></ref>
<ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>da Silva</surname> <given-names>L</given-names></name> <name><surname>Neves</surname> <given-names>BM</given-names></name> <name><surname>Moura</surname> <given-names>L</given-names></name> <name><surname>Cruz</surname> <given-names>MT</given-names></name> <name><surname>Carvalho</surname> <given-names>E</given-names></name></person-group>. <article-title>Neurotensin downregulates the pro-inflammatory properties of skin dendritic cells and increases epidermal growth factor expression</article-title>. <source>Biochim Biophys Acta</source> (<year>2011</year>) <volume>1813</volume>:<fpage>1863</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbamcr.2011.06.018</pub-id><pub-id pub-id-type="pmid">21767580</pub-id></citation></ref>
<ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname> <given-names>C</given-names></name> <name><surname>Allport</surname> <given-names>V</given-names></name> <name><surname>Loudon</surname> <given-names>J</given-names></name> <name><surname>Wu</surname> <given-names>G</given-names></name> <name><surname>Bennett</surname> <given-names>P</given-names></name></person-group>. <article-title>Nuclear factor-kappa B is essential for up-regulation of interleukin-8 expression in human amnion and cervical epithelial cells</article-title>. <source>Mol Hum Reprod</source> (<year>2001</year>) <volume>7</volume>:<fpage>787</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1093/molehr/7.8.787</pub-id><pub-id pub-id-type="pmid">11470867</pub-id></citation></ref>
<ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>H</given-names></name> <name><surname>Yang</surname> <given-names>S</given-names></name> <name><surname>Yang</surname> <given-names>Z</given-names></name> <name><surname>Ma</surname> <given-names>L</given-names></name> <name><surname>Jiang</surname> <given-names>D</given-names></name> <name><surname>Ma</surname> <given-names>J</given-names></name> <etal/></person-group> <article-title>Inhibition of GSK-3&#x003B2; decreases NF-&#x003BA;B-dependent gene expression and impairs the rat liver regeneration</article-title>. <source>J Cell Biochem</source> (<year>2007</year>) <volume>102</volume>:<fpage>1281</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1002/jcb.21358</pub-id></citation></ref>
<ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baarsma</surname> <given-names>HA</given-names></name> <name><surname>Engelbertink</surname> <given-names>LH</given-names></name> <name><surname>Hees</surname> <given-names>LJ</given-names></name> <name><surname>Menzen</surname> <given-names>MH</given-names></name> <name><surname>Meurs</surname> <given-names>H</given-names></name> <name><surname>Timens</surname> <given-names>W</given-names></name> <etal/></person-group> <article-title>Glycogen synthase kinase-3 (GSK-3) regulates TGF-&#x003B2;1-induced differentiation of pulmonary fibroblasts</article-title>. <source>Br J Pharmacol</source> (<year>2013</year>) <volume>169</volume>:<fpage>590</fpage>&#x02013;<lpage>603</lpage>.<pub-id pub-id-type="doi">10.1111/bph.12098</pub-id></citation></ref>
<ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grimes</surname> <given-names>CA</given-names></name> <name><surname>Jope</surname> <given-names>RS</given-names></name></person-group>. <article-title>CREB DNA binding activity is inhibited by glycogen synthase kinase-3&#x003B2; and facilitated by lithium</article-title>. <source>J Neurochem</source> (<year>2001</year>) <volume>78</volume>:<fpage>1219</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1046/j.1471-4159.2001.00495.x</pub-id></citation></ref>
<ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saraiva</surname> <given-names>M</given-names></name> <name><surname>O&#x02019;Garra</surname> <given-names>A</given-names></name></person-group>. <article-title>The regulation of IL-10 production by immune cells</article-title>. <source>Nat Rev Immunol</source> (<year>2010</year>) <volume>10</volume>:<fpage>170</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1038/nri2711</pub-id><pub-id pub-id-type="pmid">20154735</pub-id></citation></ref>
<ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cajero-Ju&#x000E1;rez</surname> <given-names>M</given-names></name> <name><surname>Avila</surname> <given-names>B</given-names></name> <name><surname>Ochoa</surname> <given-names>A</given-names></name> <name><surname>Garrido-Guerrero</surname> <given-names>E</given-names></name> <name><surname>Varela-Echavarr&#x000ED;a</surname> <given-names>A</given-names></name> <name><surname>de la Escalera</surname> <given-names>GM</given-names></name> <etal/></person-group> <article-title>Immortalization of bovine umbilical vein endothelial cells: a model for the study of vascular endothelium</article-title>. <source>Eur J Cell Biol</source> (<year>2002</year>) <volume>81</volume>:<fpage>1</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1078/0171-9335-00213</pub-id><pub-id pub-id-type="pmid">11893074</pub-id></citation></ref>
<ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname> <given-names>K</given-names></name> <name><surname>Bose</surname> <given-names>P</given-names></name> <name><surname>Leong-Quong</surname> <given-names>RY</given-names></name> <name><surname>Fujita</surname> <given-names>DJ</given-names></name> <name><surname>Riabowol</surname> <given-names>K</given-names></name></person-group>. <article-title>REAP: a two minute cell fractionation method</article-title>. <source>BMC Res Notes</source> (<year>2010</year>) <volume>3</volume>:<fpage>294</fpage>.<pub-id pub-id-type="doi">10.1186/1756-0500-3-294</pub-id><pub-id pub-id-type="pmid">21067583</pub-id></citation></ref>
<ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Konnai</surname> <given-names>S</given-names></name> <name><surname>Usui</surname> <given-names>T</given-names></name> <name><surname>Ohashi</surname> <given-names>K</given-names></name> <name><surname>Onuma</surname> <given-names>M</given-names></name></person-group>. <article-title>The rapid quantitative analysis of bovine cytokine genes by real-time RT-PCR</article-title>. <source>Vet Microbiol</source> (<year>2003</year>) <volume>94</volume>:<fpage>283</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="doi">10.1016/S0378-1135(03)00119-6</pub-id><pub-id pub-id-type="pmid">12829382</pub-id></citation></ref>
<ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mellett</surname> <given-names>M</given-names></name> <name><surname>Atzei</surname> <given-names>P</given-names></name> <name><surname>Jackson</surname> <given-names>R</given-names></name> <name><surname>O&#x02019;Neill</surname> <given-names>LA</given-names></name> <name><surname>Moynagh</surname> <given-names>PN</given-names></name></person-group>. <article-title>Mal mediates TLR-induced activation of CREB and expression of IL-10</article-title>. <source>J Immunol</source> (<year>2011</year>) <volume>186</volume>:<fpage>4925</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1002739</pub-id><pub-id pub-id-type="pmid">21398611</pub-id></citation></ref>
<ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andreakos</surname> <given-names>E</given-names></name> <name><surname>Sacre</surname> <given-names>SM</given-names></name> <name><surname>Smith</surname> <given-names>C</given-names></name> <name><surname>Lundberg</surname> <given-names>A</given-names></name> <name><surname>Kiriakidis</surname> <given-names>S</given-names></name> <name><surname>Stonehouse</surname> <given-names>T</given-names></name> <etal/></person-group> <article-title>Distinct pathways of LPS-induced NF-&#x003BA;B activation and cytokine production in human myeloid and nonmyeloid cells defined by selective utilization of MyD88 and Mal/TIRAP</article-title>. <source>Blood</source> (<year>2004</year>) <volume>103</volume>:<fpage>2229</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2003-04-1356</pub-id></citation></ref>
<ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname> <given-names>T</given-names></name></person-group>. <article-title>The nuclear factor NF-&#x003BA;B pathway in inflammation</article-title>. <source>Cold Spring Harb Perspect Biol</source> (<year>2009</year>) <volume>1</volume>:<fpage>a001651</fpage>.<pub-id pub-id-type="doi">10.1101/cshperspect.a001651</pub-id></citation></ref>
<ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Du</surname> <given-names>K</given-names></name> <name><surname>Asahara</surname> <given-names>H</given-names></name> <name><surname>Jhala</surname> <given-names>US</given-names></name> <name><surname>Wagner</surname> <given-names>BL</given-names></name> <name><surname>Montminy</surname> <given-names>M</given-names></name></person-group>. <article-title>Characterization of a CREB gain-of-function mutant with constitutive transcriptional activity <italic>in vivo</italic></article-title>. <source>Mol Cell Biol</source> (<year>2000</year>) <volume>20</volume>:<fpage>4320</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1128/MCB.20.12.4320-4327.2000</pub-id><pub-id pub-id-type="pmid">10825195</pub-id></citation></ref>
<ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kornhauser</surname> <given-names>JM</given-names></name> <name><surname>Cowan</surname> <given-names>CW</given-names></name> <name><surname>Shaywitz</surname> <given-names>AJ</given-names></name> <name><surname>Dolmetsch</surname> <given-names>RE</given-names></name> <name><surname>Griffith</surname> <given-names>EC</given-names></name> <name><surname>Hu</surname> <given-names>LS</given-names></name> <etal/></person-group> <article-title>CREB transcriptional activity in neurons is regulated by multiple, calcium-specific phosphorylation events</article-title>. <source>Neuron</source> (<year>2002</year>) <volume>34</volume>:<fpage>221</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1016/S0896-6273(02)00655-4</pub-id><pub-id pub-id-type="pmid">11970864</pub-id></citation></ref>
<ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>G&#x000F6;tschel</surname> <given-names>F</given-names></name> <name><surname>Kern</surname> <given-names>C</given-names></name> <name><surname>Lang</surname> <given-names>S</given-names></name> <name><surname>Sparna</surname> <given-names>T</given-names></name> <name><surname>Markmann</surname> <given-names>C</given-names></name> <name><surname>Schwager</surname> <given-names>J</given-names></name> <etal/></person-group> <article-title>Inhibition of GSK3 differentially modulates NF-&#x003BA;B, CREB, AP-1 and &#x003B2;-catenin signaling in hepatocytes, but fails to promote TNF-&#x003B1;-induced apoptosis</article-title>. <source>Exp Cell Res</source> (<year>2008</year>) <volume>314</volume>:<fpage>1351</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="doi">10.1016/j.yexcr.2007.12.015</pub-id></citation></ref>
<ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morton</surname> <given-names>S</given-names></name> <name><surname>Davis</surname> <given-names>RJ</given-names></name> <name><surname>McLaren</surname> <given-names>A</given-names></name> <name><surname>Cohen</surname> <given-names>P</given-names></name></person-group>. <article-title>A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun</article-title>. <source>EMBO J</source> (<year>2003</year>) <volume>22</volume>:<fpage>3876</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="doi">10.1093/emboj/cdg388</pub-id><pub-id pub-id-type="pmid">12881422</pub-id></citation></ref>
<ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Monick</surname> <given-names>MM</given-names></name> <name><surname>Mallampalli</surname> <given-names>RK</given-names></name> <name><surname>Carter</surname> <given-names>AB</given-names></name> <name><surname>Flaherty</surname> <given-names>DM</given-names></name> <name><surname>McCoy</surname> <given-names>D</given-names></name> <name><surname>Robeff</surname> <given-names>PK</given-names></name> <etal/></person-group> <article-title>Ceramide regulates lipopolysaccharide-induced phosphatidylinositol 3-kinase and Akt activity in human alveolar macrophages</article-title>. <source>J Immunol</source> (<year>2001</year>) <volume>167</volume>:<fpage>5977</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.167.10.5977</pub-id><pub-id pub-id-type="pmid">11698477</pub-id></citation></ref>
<ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohtani</surname> <given-names>M</given-names></name> <name><surname>Nagai</surname> <given-names>S</given-names></name> <name><surname>Kondo</surname> <given-names>S</given-names></name> <name><surname>Mizuno</surname> <given-names>S</given-names></name> <name><surname>Nakamura</surname> <given-names>K</given-names></name> <name><surname>Tanabe</surname> <given-names>M</given-names></name> <etal/></person-group> <article-title>Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells</article-title>. <source>Blood</source> (<year>2008</year>) <volume>112</volume>:<fpage>635</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2008-02-137430</pub-id><pub-id pub-id-type="pmid">18492954</pub-id></citation></ref>
<ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goc</surname> <given-names>A</given-names></name> <name><surname>Al-Husein</surname> <given-names>B</given-names></name> <name><surname>Katsanevas</surname> <given-names>K</given-names></name> <name><surname>Steinbach</surname> <given-names>A</given-names></name> <name><surname>Lou</surname> <given-names>U</given-names></name> <name><surname>Sabbineni</surname> <given-names>H</given-names></name> <etal/></person-group> <article-title>Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression <italic>in vitro</italic> and <italic>in vivo</italic></article-title>. <source>Oncotarget</source> (<year>2014</year>) <volume>5</volume>:<fpage>775</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="doi">10.18632/oncotarget.1770</pub-id><pub-id pub-id-type="pmid">24519956</pub-id></citation></ref>
<ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shenkar</surname> <given-names>R</given-names></name> <name><surname>Yum</surname> <given-names>H-K</given-names></name> <name><surname>Arcaroli</surname> <given-names>J</given-names></name> <name><surname>Kupfner</surname> <given-names>J</given-names></name> <name><surname>Abraham</surname> <given-names>E</given-names></name></person-group>. <article-title>Interactions between CBP, NF-&#x003BA;B, and CREB in the lungs after hemorrhage and endotoxemia</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> (<year>2001</year>) <volume>281</volume>:<fpage>L418</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="doi">10.1152/ajplung.2001.281.2.L418</pub-id></citation></ref>
<ref id="B45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Venza</surname> <given-names>I</given-names></name> <name><surname>Cucinotta</surname> <given-names>M</given-names></name> <name><surname>Caristi</surname> <given-names>S</given-names></name> <name><surname>Mancuso</surname> <given-names>G</given-names></name> <name><surname>Teti</surname> <given-names>D</given-names></name></person-group>. <article-title>Transcriptional regulation of IL-8 by <italic>Staphylococcus aureus</italic> in human conjunctival cells involves activation of AP-1</article-title>. <source>Invest Ophthalmol Vis Sci</source> (<year>2007</year>) <volume>48</volume>:<fpage>270</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1167/iovs.06-0081</pub-id><pub-id pub-id-type="pmid">17197543</pub-id></citation></ref>
<ref id="B46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deplanche</surname> <given-names>M</given-names></name> <name><surname>Alekseeva</surname> <given-names>L</given-names></name> <name><surname>Semenovskaya</surname> <given-names>K</given-names></name> <name><surname>Fu</surname> <given-names>C-L</given-names></name> <name><surname>Dessauge</surname> <given-names>F</given-names></name> <name><surname>Finot</surname> <given-names>L</given-names></name> <etal/></person-group> <article-title><italic>Staphylococcus aureus</italic> phenol-soluble modulins impair interleukin expression in bovine mammary epithelial cells</article-title>. <source>Infect Immun</source> (<year>2016</year>) <volume>84</volume>:<fpage>1682</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="doi">10.1128/IAI.01330-15</pub-id><pub-id pub-id-type="pmid">27001539</pub-id></citation></ref>
<ref id="B47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname> <given-names>GY</given-names></name> <name><surname>Joo</surname> <given-names>HS</given-names></name> <name><surname>Chatterjee</surname> <given-names>SS</given-names></name> <name><surname>Otto</surname> <given-names>M</given-names></name></person-group>. <article-title>Phenol-soluble modulins-critical determinants of staphylococcal virulence</article-title>. <source>FEMS Microbiol Rev</source> (<year>2014</year>) <volume>38</volume>:<fpage>698</fpage>&#x02013;<lpage>719</lpage>.<pub-id pub-id-type="doi">10.1111/1574-6976.12057</pub-id></citation></ref>
<ref id="B48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steinbrink</surname> <given-names>K</given-names></name> <name><surname>W&#x000F6;lfl</surname> <given-names>M</given-names></name> <name><surname>Jonuleit</surname> <given-names>H</given-names></name> <name><surname>Knop</surname> <given-names>J</given-names></name> <name><surname>Enk</surname> <given-names>AH</given-names></name></person-group>. <article-title>Induction of tolerance by IL-10-treated dendritic cells</article-title>. <source>J Immunol</source> (<year>1997</year>) <volume>159</volume>:<fpage>4772</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">9366401</pub-id></citation></ref>
<ref id="B49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schreiner</surname> <given-names>J</given-names></name> <name><surname>Kretschmer</surname> <given-names>D</given-names></name> <name><surname>Klenk</surname> <given-names>J</given-names></name> <name><surname>Otto</surname> <given-names>M</given-names></name> <name><surname>B&#x000FC;hring</surname> <given-names>H-J</given-names></name> <name><surname>Stevanovic</surname> <given-names>S</given-names></name> <etal/></person-group> <article-title><italic>Staphylococcus aureus</italic> phenol-soluble modulin peptides modulate dendritic cell functions and increase <italic>in vitro</italic> priming of regulatory T cells</article-title>. <source>J Immunol</source> (<year>2013</year>) <volume>190</volume>:<fpage>3417</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1202563</pub-id><pub-id pub-id-type="pmid">23460735</pub-id></citation></ref>
<ref id="B50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tuchscherr</surname> <given-names>L</given-names></name> <name><surname>Medina</surname> <given-names>E</given-names></name> <name><surname>Hussain</surname> <given-names>M</given-names></name> <name><surname>V&#x000F6;lker</surname> <given-names>W</given-names></name> <name><surname>Heitmann</surname> <given-names>V</given-names></name> <name><surname>Niemann</surname> <given-names>S</given-names></name> <etal/></person-group> <article-title><italic>Staphylococcus aureus</italic> phenotype switching: an effective bacterial strategy to escape host immune response and establish a chronic infection</article-title>. <source>EMBO Mol Med</source> (<year>2011</year>) <volume>3</volume>:<fpage>129</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1002/emmm.201000115</pub-id><pub-id pub-id-type="pmid">21268281</pub-id></citation></ref>
<ref id="B51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sutherland</surname> <given-names>C</given-names></name></person-group>. <article-title>What are the bona fide GSK3 substrates?</article-title> <source>Int J Alzheimers Dis</source> (<year>2011</year>) <volume>2011</volume>:<fpage>505607</fpage>.<pub-id pub-id-type="doi">10.4061/2011/505607</pub-id><pub-id pub-id-type="pmid">21629754</pub-id></citation></ref>
<ref id="B52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>P</given-names></name> <name><surname>Katz</surname> <given-names>J</given-names></name> <name><surname>Michalek</surname> <given-names>SM</given-names></name></person-group>. <article-title>Glycogen synthase kinase-3&#x003B2; (GSK3&#x003B2;) inhibition suppresses the inflammatory response to <italic>Francisella</italic> infection and protects against tularemia in mice</article-title>. <source>Mol Immunol</source> (<year>2009</year>) <volume>46</volume>:<fpage>677</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="doi">10.1016/j.molimm.2008.08.281</pub-id></citation></ref>
<ref id="B53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname> <given-names>MM</given-names></name> <name><surname>Cheung</surname> <given-names>BK</given-names></name> <name><surname>Li</surname> <given-names>JC</given-names></name> <name><surname>Chan</surname> <given-names>LL</given-names></name> <name><surname>Lau</surname> <given-names>AS</given-names></name></person-group>. <article-title>A role for glycogen synthase kinase-3 in antagonizing mycobacterial immune evasion by negatively regulating IL-10 induction</article-title>. <source>J Leukoc Biol</source> (<year>2009</year>) <volume>86</volume>:<fpage>283</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1189/jlb.0708442</pub-id><pub-id pub-id-type="pmid">19401395</pub-id></citation></ref>
<ref id="B54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname> <given-names>M</given-names></name> <name><surname>Hisatsune</surname> <given-names>J</given-names></name> <name><surname>Yamasaki</surname> <given-names>E</given-names></name> <name><surname>Isomoto</surname> <given-names>H</given-names></name> <name><surname>Kurazono</surname> <given-names>H</given-names></name> <name><surname>Hatakeyama</surname> <given-names>M</given-names></name> <etal/></person-group> <article-title><italic>Helicobacter pylori</italic> VacA-induced inhibition of GSK3 through the PI3K/Akt signaling pathway</article-title>. <source>J Biol Chem</source> (<year>2009</year>) <volume>284</volume>:<fpage>1612</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M806981200</pub-id><pub-id pub-id-type="pmid">18996844</pub-id></citation></ref>
<ref id="B55"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname> <given-names>HB</given-names></name> <name><surname>Shaw</surname> <given-names>PC</given-names></name> <name><surname>Wong</surname> <given-names>CC</given-names></name> <name><surname>Wan</surname> <given-names>DC</given-names></name></person-group>. <article-title>Expression of glycogen synthase kinase-3 isoforms in mouse tissues and their transcription in the brain</article-title>. <source>J Chem Neuroanat</source> (<year>2002</year>) <volume>23</volume>:<fpage>291</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/S0891-0618(02)00014-5</pub-id><pub-id pub-id-type="pmid">12048112</pub-id></citation></ref>
<ref id="B56"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname> <given-names>KF</given-names></name> <name><surname>Miller</surname> <given-names>CJ</given-names></name> <name><surname>Anderton</surname> <given-names>BH</given-names></name> <name><surname>Shaw</surname> <given-names>PC</given-names></name></person-group>. <article-title>Expression analysis of glycogen synthase kinase-3 in human tissues</article-title>. <source>J Pept Res</source> (<year>1999</year>) <volume>54</volume>:<fpage>85</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1034/j.1399-3011.1999.00083.x</pub-id><pub-id pub-id-type="pmid">10448973</pub-id></citation></ref>
<ref id="B57"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname> <given-names>R</given-names></name> <name><surname>Nagini</surname> <given-names>S</given-names></name> <name><surname>Rana</surname> <given-names>A</given-names></name></person-group>. <article-title>Expression and inactivation of glycogen synthase kinase 3 alpha/beta and their association with the expression of cyclin D1 and p53 in oral squamous cell carcinoma progression</article-title>. <source>Mol Cancer</source> (<year>2015</year>) <volume>3</volume>:<fpage>14</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1186/s12943-015-0300-x</pub-id><pub-id pub-id-type="pmid">25645517</pub-id></citation></ref>
<ref id="B58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname> <given-names>MH</given-names></name> <name><surname>Chuang</surname> <given-names>D-M</given-names></name></person-group>. <article-title>Differential roles of glycogen synthase kinase-3 isoforms in the regulation of transcriptional activation</article-title>. <source>J Biol Chem</source> (<year>2006</year>) <volume>281</volume>:<fpage>30479</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M607468200</pub-id><pub-id pub-id-type="pmid">16912034</pub-id></citation></ref>
<ref id="B59"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gulen</surname> <given-names>MF</given-names></name> <name><surname>Bulek</surname> <given-names>K</given-names></name> <name><surname>Xiao</surname> <given-names>H</given-names></name> <name><surname>Yu</surname> <given-names>M</given-names></name> <name><surname>Gao</surname> <given-names>J</given-names></name> <name><surname>Sun</surname> <given-names>L</given-names></name> <etal/></person-group> <article-title>Inactivation of the enzyme GSK3&#x003B1; by the kinase IKKi promotes AKT-mTOR signaling pathway that mediates interleukin-1-induced Th17&#x02009;cell maintenance</article-title>. <source>Immunity</source> (<year>2012</year>) <volume>37</volume>:<fpage>800</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2012.08.019</pub-id><pub-id pub-id-type="pmid">23142783</pub-id></citation></ref>
<ref id="B60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>SA</given-names></name> <name><surname>Lee</surname> <given-names>JW</given-names></name> <name><surname>Herbst</surname> <given-names>RS</given-names></name> <name><surname>Koo</surname> <given-names>JS</given-names></name></person-group>. <article-title>GSK-3&#x003B1; is a novel target of CREB and CREB-GSK-3&#x003B1; signaling participates in cell viability in lung cancer</article-title>. <source>PLoS One</source> (<year>2016</year>) <volume>11</volume>:<fpage>e0153075</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0153075</pub-id><pub-id pub-id-type="pmid">27049759</pub-id></citation></ref>
</ref-list>
</back>
</article>